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In an era of increasingly personalized medical care, radiation therapy (RT) continues to be 
a prominent and effective focal cancer treatment. However, the standard RT treatment process 
remains largely uniform, using a one-size-fits-all approach designed to maximize therapeutic 
benefit to patient populations typically stratified only by tumor type, anatomical location, and 
extent of the disease. However, additional factors within these populations may lead individual 
patients to respond differently to RT during and after treatment. Therefore, current RT treatment 
practices and processes are likely suboptimal for individual patients and could be better tailored to 
each patient by incorporating additional patient-specific information into the RT planning and 
treatment evaluation processes. To facilitate this, actionable treatment response models that 
account for patient variability must be developed and implemented. These models can be 
formulated though analysis of anatomical and functional changes observed within patient imaging 
and by evaluating treatment outcomes based on underlying biological factors in addition to the 
therapeutic intervention. This dissertation includes multiple investigations focused on developing 
and implementing patient-specific models to support personalized, evidence-based RT. 
Advancements in anatomical and functional patient imaging have allowed for non-invasive 
evaluation and analysis of changes throughout the course of RT and follow-up care. Accurate 
spatial alignment of patient imaging is required to incorporate these new imaging techniques into 
the RT planning process, evaluate treatment response, and better correlate anatomical and 
functional changes to therapeutic radiation delivery. However, the ability to link and compare 
imaging studies before, during, and after treatment is often obscured by significant spatial and 
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volumetric variations caused by physiological and treatment-related factors. To address this, we 
conducted a series of studies on geometrically-based patient modeling to improve the accuracy of 
deformable image registration (DIR) and evaluate the clinical impact. First, an intensity-based DIR 
algorithm was characterized in the context of modern clinical imaging scenarios. Algorithm 
parameters were evaluated with respect to clinical accuracy metrics and dosimetric impact. Next, 
radiation dose, in combination with patient factors including tumor location and type, were used 
to biomechanically model longitudinal liver anatomy changes during RT and follow-up care. A 
previously developed biomechanical DIR algorithm was modified to incorporate the newly 
developed liver-response models and was shown to improve spatial and volumetric correlation. 
Following studies in geometric patient modeling, we studied the direct incorporation of 
patient-specific response models into the RT planning process. Through a prioritized fluence 
optimization approach, we implemented the concept of utility-based planning where the 
optimization objective is to maximize the predicted value of overall treatment utility for a patient, 
defined by the probability of efficacy (e.g., local control) minus the weighted sum of toxicity 
probabilities. Implementation of the prioritized utility-based optimization strategy offers an 
intuitive approach to biological optimization in which planning trade-offs are explicitly optimized. 
The feasibility of this new planning approach was demonstrated on a cohort of non-small cell lung 
cancer patients and was shown to improve overall plan utility through situational tumor dose 
modification and normal tissue dose redistribution. 
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Chapter 1  
Introduction 
 
1.1 Radiation Therapy 
Despite advances in the biological understanding of cancer and the development of new 
treatments, cancer continues to be the leading cause of death globally.1 Furthermore, the burden 
of cancer incidence and mortality continues to grow rapidly worldwide, driven in part by aging 
populations and increasing cancer risk factors associated with globalization and developing 
economies.1 Radiation therapy (RT) plays a central role in the management of cancer, both in the 
US and worldwide, with a majority of cancer patients benefiting from RT at some point during 
their care.2,3 Over the last decade, technological advancements throughout the RT workflow, 
summarized in Figure 1.1, have aimed to increase the precision of RT, improve tumor control, and 
decrease toxicity with the underlying goal of delivering therapeutic radiation doses to tumors while 
attempting to avoid radiation damage to surrounding normal tissues. This includes advancements 
in pre-treatment imaging, where the incorporation of magnetic resonance imaging (MRI) and 
functional imaging, in addition to the standard-of-care computed tomography (CT) imaging, has 
provided physicians with improved visualization of tumor structures and organs, facilitating 
precise identification of target and normal tissue volumes for treatment planning.4,5  Improvements 
in image registration tools, which provide the ability to spatially correlate data from multiple 
imaging sources, have contributed to the ability to delineate these structures, allowing for 
physicians to simultaneously use multiple imaging datasets to contour structures.5 Additionally, 
accurate image registration has permitted improved flow of patient imaging data into the treatment 
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planning process, empowering treatment planning to be based on not only anatomical data, but 
also functional imaging data (e.g., functional avoidance planning).6 
 
Figure 1.1. External beam radiation therapy treatment planning workflow including pre-treatment imaging, 
treatment planning, and treatment delivery. First a patient receives pre-treatment imaging. This is typically in 
the form of a CT scan, but also can include MR imaging and nuclear medicine studies to help visualize 
anatomical structures and quantify organ function for treatment planning. Then imaging data is correlated 
through image registration allowing for accurate contouring of tumor and normal tissue volumes across the 
multiple imaging modalities. Anatomical information is then used to create and optimize a personalized 
treatment plan (dose distribution) with the goal of delivering radiation to the tumor while avoiding surrounding 
normal tissues. Following the creation of an acceptable plan, radiation is delivered to the patient with assistance 
from image guidance. The process can be repeated if the patient responds to therapy or if anatomical changes 
occur during the course of treatment. Machine images from Philips Healthcare (Amsterdam, Netherlands), 
Siemens Healthineers (Erlangen, Germany), and Varian Medical System (Palo Alto, CA). 
  
The impact of improved imaging continues to treatment delivery, where daily 3D image 
guidance through in room cone-beam CT (CBCT) decreases patient setup variations and, when 
combined with image registration, enables tracking of patient response and delivered dose.7 
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Similarly, in RT treatment planning, technological and engineering advancements in treatment 
delivery, along with advancements in computing, have made it possible to develop highly 
conformal intensity-modulated RT (IMRT) treatment plans (i.e., beam trajectories and fluence 
intensities) that can be accurately delivered to the patient.8 Additionally, it is now feasible to iterate 
through the treatment planning process, adapting a patient’s treatment plan to account for 
anatomical and biological changes that present during the course of RT.9 
 With these advancements and others increasing the precision in RT treatments, it has 
become evident that increased personalization may also be possible. This represents a potential 
paradigm shift in RT, which has been historically known for employing ‘one-size-fits-all’ 
approaches, such as using uniform prescription doses and applying population-level normal-tissue 
dose constraints in treatment planning.  However, incorporating patient-specific data into RT poses 
many challenges, from understanding the accuracy and limitations of new technologies to 
determining how and when to act on information not previously available or considered. This 
thesis focuses on multiple approaches working towards incorporating patient-specific response 
into RT. This encompasses steps related to generating improved anatomical and physiological 
patient models and the ability to directly intervene on the basis of such models.  
 
1.2 Deformable Image Registration 
Patient management throughout oncology care increasingly relies upon imaging for non-
invasive diagnosis, response assessment, and follow-up care.10 Although advancements in imaging 
have improved care broadly across oncology, patient imaging is particularly important in RT, 
serving as an essential component for the accurate delivery of radiation.11 Prior to treatment, 
imaging is used to visualize the extent of disease, delineate the position of the tumor and 
surrounding normal-tissue structures for treatment planning, calculate radiation dose, and assess 
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the functional capacity or distribution of radiation-sensitive organs.12,13 This process may include 
gathering and integrating data from multiple imaging modalities to provide physicians increased 
insight into the patient and disease. For example, some modalities may be focused on improving 
the anatomical targeting accuracy of treatment by providing better visualization of the boundary 
or motion of the tumor (e.g., 4DCT, MRI), while others are focused on quantitatively estimating 
tumor cell metabolism or organ function (e.g., positron emission tomography (PET), Dynamic 
Contrast-Enhanced (DCE) MRI).13,14 
Furthermore, advancements in the technical capabilities of radiation detectors and 
reconstruction techniques have enabled the use of imaging during treatment to improve the 
precision and accuracy of the actual treatment delivery, which can occur days after initial patient 
imaging and across multiple treatment sessions.15,16 In addition to improving the spatial targeting 
of radiation delivery at the time of treatment, image-guided radiation therapy (IGRT) through on-
board imaging modalities (e.g., CBCT, MRI) also provides the opportunity to visualize anatomical 
and physiological changes over the course of treatment. This enables clinicians to non-invasively 
monitor and track the tumor’s response to radiation in addition to factors attributed to increased 
patient setup errors, such as patient weight loss, that can lead to decreased treatment efficacy and 
unnecessary radiation-induced toxicity. In the presence of anatomical or physiological changes 
that cause the treatment to deviate from the original, intended RT plan, there is a potential to 
intervene by adjusting or re-planning the RT treatment based on a more recent anatomical 
representation and clinical presentation of the patient.17-20 Applications of these methods, referred 
to broadly as adaptive radiotherapy, have become increasingly popular in RT and have the 
potential to directly improve patient outcomes as a result of more personalized, precise, and 
accurate treatment. Numerous clinical trials (e.g., NCT01504815, NCT03416153, NCT04751747) 
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are currently underway to investigate the application and determine the effectiveness of adaptive 
RT for multiple anatomical locations and cancer types.  
Another application for imaging data collected during IGRT is to longitudinally reconstruct 
the actual dose delivered to the patient over the course of treatment factoring in daily variations in 
patient setup and anatomy.21 While gathering this information at the individual level can be useful 
in determining when and if to adapt a patient’s treatment, it may also be useful in generating more 
accurate representations of patient dose (i.e., delivered dose compared to planned dose) for 
efficacy and toxicity modeling at the population level. Understanding the link between radiation 
and patient outcomes (e.g., tumor control, toxicity) is fundamental to the clinical success of RT. 
However, historical models relating dose to patient outcomes, such as tumor-control probability 
(TCP) and normal-tissue-complication probability (NTCP) models, have been based on the 
original, planned dose to a patient, despite the known presence of anatomical and patient-
positioning variations throughout treatment. Multiple studies have demonstrated that a more 
accurate representation of radiation dose accumulated in tumors and normal tissues over the 
complete course of RT can be more predictive of patient outcomes than planned dose.22,23 
Furthermore, updated models incorporating the accumulated, or delivered, dose can impact clinical 
treatment decisions related to tumor dose selection and normal-tissue dose limits.24 
With the wealth of imaging data now available in RT and the development of related 
applications, accurate spatial alignment of images acquired from various imaging modalities at 
different time points for a patient is a critical step to enable effective clinical use for both 
qualitative and quantitative assessments. The goal of image registration is to provide accurate 
spatial alignment of two image datasets by determining the spatial transformation that exists 
between the images.  
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Generally speaking, this transformation can either be represented by a rigid registration, 
where the transformation is limited to uniform translation and/or rotation, or a non-rigid 
(deformable) registration, where the transformation can vary in magnitude and direction across the 
image. While rigid registration has become a common tool for 2D and 3D data fusion in RT, such 
as its use for daily patient positioning, it is inherently limited by the degrees of freedom present 
within the transformation (up to six parameters, three for translation and three for rotation) and 
cannot accurately represent shape changes, volume changes, or distortion between structures 
within the two image datasets.25 Determining the optimal set of parameters for a rigid registration 
is relatively easy and is largely considered a solved issue in RT. Alternatively, deformable image 
registration (DIR) has the ability to model complex, spatially-variant anatomical changes that 
occur within the human body between image acquisitions and over the course of treatment. 
However, solving for the optimal DIR between two images is computationally more challenging, 
with the number of parameters extending up to three times the number of voxels within the dataset 
(i.e., a deformation vector field (DVF) comprised of independent 3D translation vectors for each 
voxel). Although the concept of DIR is almost four decades old and many algorithms have been 
proposed, a renewed interest in this area of research has been generated by increased computational 
abilities, more broadly adopted IGRT, and the growing field of adaptive RT.25-30 These solutions 
can be grouped into two general categories, intensity-based approaches (e.g., B-spline, Demons) 
and geometric approaches (e.g., Chamfer, biomechanical finite element), both of which are 
investigated in this thesis.25 Figure 1.2 shows an example intensity-based deformable registration 
between lung images of the same patient at different time points. 
 7 
 
Figure 1.2. Example of intensity-based DIR for a lung patient with CT images acquired in different breathing 
states. Image A shows a deep exhale CT, Image B shows a breath-hold treatment planning CT, and Image C 
shows an overlay of the images with the DIR calculated DVF. 
 
 Intensity-based DIR methods use similarities between numerical greyscale information 
(e.g.,  Hounsfield units, MRI signal intensity) within two image datasets to generate a 
transformation spatially linking the images. The registration parameters composing the 
transformation can be based on global spline-based interpolation methods (thin-plate splines) 
where movement of control points influences deformation globally, local spline-based models (B-
splines) where a weighted grid of basis functions influences the deformation locally, or optical 
flow models (e.g., demons) where local voxel motion is determined by intensity gradients. 
Regardless of the transformation model, registration parameters are optimized based on the 
measured similarity of spatially overlapping image intensities within the two images. Depending 
on the image types, this similarity metric is typically calculated using either the image intensities 
directly, in the form of normalized cross-correlation (for singular-modality DIR), or the joint 
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probability distribution functions of image intensity levels (i.e., voxels grouped based on similar 
intensities) in the form of mutual information (for multi-modality DIR).25 
 Geometric methods offer an alternative approach to using image intensity information to 
optimize and generate the transformation. First, corresponding point-based landmarks and/or 
anatomical surfaces are identified in the images. These features are then extracted from the images 
and are used to drive the registration through point or surface matching. In general, these methods 
also require an interpolation or re-sampling method, similar to those used in intensity-based 
methods, to convert the point and surface transformations back into a transformation that can be 
applied to the entire image.  One method for preserving the physical integrity of the global 
transform is to use biomechanical finite element models (FEMs) of the deforming tissues in which 
realistic material properties, such as the stiffness and Poisson’s ratio of the tissue, are assigned to 
each of the specific tissue types present in the image. An example DIR algorithm using this 
approach is shown in Figure 1.3. Although this may produce more physically plausible 
deformations when compared to intensity-based DIR methods, biomechanical methods require 
delineation of organs, tumors, or corresponding points prior to registration. Historically this has 
been a time-consuming manual task, but advancements in deep learning techniques for image 
segmentation could soon provide robust, automated pathways for segmentation and increase the 
adoption of biomechanical DIR in RT.31 
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Figure 1.3. Example workflow of Morfeus, a FEM-based biomechanical DIR algorithm, for a liver patient. 
First the liver volumes are manually delineated and converted into 3D finite-element meshes with realistic 
material properties. Then, through surface correlation, boundary conditions are created and fed into a finite 
element analysis (FEA) solver to generate a DVF. 
 
1.3 Treatment Plan Optimization 
 The overall goal of RT is to deliver a therapeutic dose of radiation to a tumor while 
avoiding radiation damage to nearby organs. In external beam RT (EBRT), the main type of RT 
that we focus on in this dissertation, it is not possible to irradiate cancer cells without 
simultaneously irradiating surrounding tissue. Although advancements in image guidance and 
delivery techniques have improved the precision and conformality of EBRT, radiation beams still 
transverse normal tissues before and after converging on the target structure. EBRT treatment plan 
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optimization aims to create a dose distribution, dependent on beam angles, collimator shapes, and 
fluence patterns, that maximizes radiation dose within the tumor to achieve local control and 
minimizes the dose within normal tissues to decrease treatment-related acute and late morbidities. 
This aim is embodied in the concept of the therapeutic window, shown in Figure 1.4, in which plan 
optimization aims to maximize the therapeutic window through increasing the probability of tumor 
control with awareness of the increasing probability of normal tissue toxicities at higher doses. 
 
Figure 1.4. TCP and NTCP curves demonstrating the therapeutic window in radiation therapy. At any given 
radiation dose, there is a probability of tumor control and normal-tissue toxicity. The separation between 
tumor control and toxicity represents the therapeutic window (or therapeutic ratio). 
 
In the mid-1990s, the emergence of 3D imaging, the development of 3D treatment planning 
systems, and computer-controlled treatment machines equipped with multileaf collimators 
(MLCs) ushered in an era of 3D conformal RT (3D-CRT).32,33 The implementation of 3D-CRT 
was largely based on the concept of forward planning, in which appropriate beam angles and 
collimator shapes were first determined by a treatment planner.34 Then, using a uniform or linearly 
varying fluence pattern, the planner calculates the required machine output necessary to achieve 
the prescription dose. This tended to be a manual, iterative process, requiring the planner to revisit 
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the selected beam angles and collimator shapes, then recalculate the machine output, to generate a 
treatment plan that satisfied the planning goals.35 
Advancements in computing, particularly those related to dose calculation and 
optimization methods, led to the development of inverse planning, which is not only a more 
automated approach to generating treatment plans but also can improve normal tissue sparing 
while still delivering a therapeutic dose to the tumor. In inverse planning, treatment planning goals, 
typically represented by numerical criteria in the form of dose metrics, are combined into an 
objective function that is then optimized to generate a plan. The concept of inverse planning has 
allowed treatment planners to also explore the use of non-linear fluence patterns that were not 
conceivable in manual planning. This planning technique, referred to as intensity modulated 
radiation therapy (IMRT), has become common practice in RT, providing even greater conformal 
shaping of dose distributions than 3DCRT.36 
In this dissertation, the concept of beamlet-based inverse planning is used to create 
personalized treatment plans. In this method, also referred to as fluence map optimization, the 
inverse optimization problem is solved for a distribution of beamlet weights that minimize the dose 
to normal tissue structures, defined by dose metrics included in the optimization objective function, 
subject to constraints on competing metrics of tumor dose and coverage. Beamlets are defined by 
segmenting the larger beams at each beam angle into smaller sub-beams whose optimal intensity, 
or weight, can be solved for during optimization. Typically, this requires beam directions to be 
defined prior to optimization so that the individual dose contributions of beamlets to discretized 
points in the patient, representing tumor and normal tissue volumes, can be calculated. A visual 
overview of this IMRT planning process is shown in Figure 1.5. Historically, the objective 
functions used in inverse IMRT planning have been defined using dose metrics as the optimization 
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criteria; however, these metrics are only surrogate measures of tumor and normal tissue dose 
response. Recently there has been increased interest in developing techniques that move beyond 
the use of simple dose metrics for planning criteria, and instead represent the inverse RT planning 
problem directly based on patient response and treatment outcomes.37 Chapter 4 focuses on these 




Figure 1.5. Visual overview of IMRT planning for a head and neck cancer patient. First, beams are arranged 
around the patient (Image 1) and dose calculation is performed to determine the contribution of smaller 
segmented beams, ‘beamlets,’ to points within the patient. Then a numerical optimization objective is defined 
and the beamlet-weight optimization problem is solved to determine the optimal fluence patterns (Image 2) for 
each beam.  Optimal fluence is then turned into a physically deliverable plan through calculating patterns of 
MLC (Image 3) motion with the final dose distribution (Image 4) calculated after this motion is determined. 
Image 3 provided by Varian Medical System (Palo Alto, CA). 
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1.4 Goals and Organization of this Dissertation 
The generation and incorporation of patient-specific response models in RT has the 
potential to improve disease control and lower toxicity rates. In part, the creation of more 
personalized response models requires accurate image registration to spatially correlate and 
analyze longitudinal changes in patient anatomy and organ function. Additionally, image 
registration is required to more accurately determine the delivered dose to patient, which could 
improve the accuracy and applicability of historical and newly-generated TCP and NTCP models. 
Once new or updated models are created, clinical interventions need to modified to allow for 
inclusion of patient-specific information in the treatment planning process. This thesis focuses on 
these aspects of personalized radiation therapy through (Ch. 2) quantitative characterization of an 
intensity-based DIR algorithm, (Ch. 3) development and evaluation of a DIR algorithm 
incorporating patient-specific dose-based response, and (Ch. 4) implementation of a patient-
specific response models in RT treatment planning. The end of each chapter includes an 
“extensions” section which briefly describes additional studies related to the primary foci of this 
dissertation. This includes co-authored and ongoing studies that are based on work developed 
during the course of this research.  
In Chapter 2, titled “Clinical Characterization of an Intensity-Based Deformable Image 
Registration,” a comprehensive evaluation of a clinically implemented intensity-based DIR 
algorithm is presented using quantitative metrics of registration accuracy. The sensitivity of the 
DIR algorithm to varying input parameters was explored and we demonstrated that registration 
accuracy could be improved, but only in certain anatomical locations. 
In Chapter 3, titled “Characterization and Implementation of Radiation-Induced Dose-
Volume Liver Response for Biomechanical Deformable Image Registration,” a novel 
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biomechanical modeling method for hepatic tissue including independent dose-driven deformation 
forces was developed and implemented on a series of primary and metastatic liver cancer patients. 
The proposed DIR technique demonstrated improved target registration and deformed segment 
volume accuracy for longitudinal patient modeling when compared with a previously developed 
biomechanical DIR algorithm. 
In Chapter 4, titled “Incorporation of Patient-Specific Efficacy and Toxicity Estimates in 
Radiation Therapy Plan Optimization,” a novel IMRT optimization strategy is introduced that 
directly incorporates patient-specific dose response models into the planning process. In this 
strategy, we integrate the concept of utility-based planning where the optimization objective is to 
maximize the predicted value of overall treatment utility, defined by the probability of efficacy 
minus the weighted sum of toxicity probabilities. We believe that implementation of the utility-
based objective function offers an intuitive approach to biological optimization in which planning 
trade-offs are explicitly optimized. To demonstrate the feasibility of the approach, we apply the 





Chapter 2  




Portions of this chapter are substantially equivalent to work the author previously 




Image registration tools have become more commonly available in commercial 
radiotherapy software systems over the last decade. Despite this availability, the clinical adoption 
and use of these tools, particularly deformable image registration (DIR), remains limited in part 
due to the inability to quantitatively evaluate and characterize the performance of the system. 
Additionally, many clinically available DIR implementations do not incorporate the necessary 
tools required to robustly test user-controlled parameters or do not even allow users to adjust 
algorithm parameters. In this study, we aim to quantitatively evaluate an intensity-based DIR 
algorithm for numerous clinically relevant imaging situations, including single and multi-modality 
images. Additionally, through the creation of a new scripting interface, we characterize the 
performance of the algorithm across a range of input parameters to determine the sensitivity of 
registration accuracy to the algorithm. In this retrospective study, the DIR algorithm was evaluated 
for patients in each of the following anatomical locations: head and neck (HN), liver, male pelvis 
and female pelvis. HN DIRs were evaluated from planning-CT (pCT) to repeat-pCT and pCTs to 
daily CBCTs using dice similarity coefficients (DSC) and mean distance to agreement (MDA) of 
corresponding anatomical structures. Male pelvis DIRs were evaluated from pCT to CBCTs using 
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DSC, MDA, and target registration error (TRE) of implanted radiofrequency (RF) beacons within 
the prostate. Liver DIRs were evaluated from pMR to pCT using DSC and TRE of vessel 
bifurcations. Female pelvis DIRs were evaluated between fractionated brachytherapy MRIs using 
DSC and MDA of corresponding anatomical structures. Registration algorithm parameters, 
including those related to the image intensity histogram, deformation model, and optimization 
process, were tested on the HN and lung cases with both pCT and daily CBCT imaging. Evaluation 
of the algorithm demonstrated clinically acceptable DIR accuracy for lung pCT-CBCT. Near 
clinically acceptable accuracy was achieved for head and neck (pCT-pCT and pCT-CBCT), lung 
4DCT, and GYN MR-MR. Clinically acceptable accuracy was not achieved in liver MR-CT and 
prostate CT-CBCT. Analysis of registration parameter sensitivity demonstrated that a large 
improvement in registration accuracy could be achieved in lung cases, but only a marginal and 
variable improvement could be achieved for head and neck cases. Overall this work demonstrates 
that although clinically acceptable DIR accuracy can be achieved in some imaging situations with 
class-level DIR algorithm parameter selection, refinement of the parameters for specific 
anatomical locations may significantly improve accuracy. However, for certain clinical 
applications, registration accuracy of intensity-based DIR is relatively insensitive to algorithm 
parameters and other DIR techniques should be considered. 
2.2 Introduction 
 Throughout the cancer care continuum, technological advancements in minimally or non-
invasive patient imaging have transformed the detection, treatment, and management of cancer. 
Improved detection, signal processing, and reconstruction techniques in computed tomography 
(CT), magnetic resonance (MR) imaging, and tomographic nuclear medicine imaging have 
improved the spatial accuracy of anatomical imaging, increased the ability to differentiate different 
 17 
tissue types in the body, and have facilitated wider-spread adoption of functional, or physiological, 
imaging to guide treatment.  With these advancements, modern radiation therapy has become an 
increasingly image-rich environment where the quantitative use of imaging to calculate dose, 
delineate structures, and position daily treatment is fundamental to the precise delivery of 
radiation.38 In a modern RT clinic, patients may receive numerous pre-treatment imaging studies, 
including CT imaging for normal tissue contouring, dose calculation, and motion characterization, 
MR imaging for improved visualization of tumors in soft tissue and functional assessment, and 
nuclear medicine studies for characterization of tumorigenic activity and additional functional 
assessment.39,40 Additionally, with the extensive use of image-guided radiation therapy (IGRT), 
driven by the development of in-room or on-board 3D imaging devices, patients may receive daily 
CT, cone-beam CT (CBCT), or MR imaging to guide precision delivery of radiation and track 
treatment response.41-43 While individually each of these imaging techniques serves an important 
purpose in guiding treatment, the true potential of multimodality, multi-instance imaging in RT 
can only be realized when imaging datasets can be spatially linked together for quantitative and 
qualitative assessment.  
Rigid registration of image datasets, through global translation and rotation parameters, 
provides one method of spatially correlating imaging data. However, this method is only sufficient 
for anatomical sites with rigid body motion (e.g., brain, bones) and is ill-suited for portions of the 
body that are subject to complex physiological motion (e.g., lungs, bowel) or motion caused by 
external forces such as gravity. Furthermore, longitudinal imaging assessments may demonstrate 
changes in morphology and anatomy caused by treatment interventions (e.g., tumor shrinkage) 
and/or body habitus changes unrelated to treatment.47,48 Non-rigid, deformable image registration 
(DIR) offers a spatial alignment solution that has the potential to account for complex 
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physiological motion and changes in anatomy. While rigid-registration may be limited to 6 
parameters to determine spatial alignment, DIR offers the ability for every voxel in an image 
dataset to move independently. In medical imaging, however, it is highly unlikely that every voxel 
within an imaging dataset moves independently, therefore multiple DIR algorithms have been 
proposed to create physically-plausible deformations.46-51 
Despite the breadth of work invested in creating new DIR algorithms, the quantitative 
assessment of DIR accuracy has remained limited.52 Even with commercial adoption of DIR 
algorithms, robust clinical evaluations of DIR implementations are sparse, in part due to the lack 
of proper quantitative evaluation tools within commercial software systems.25 A recent report from 
the American Association of Physicists in Medicine (AAPM) has highlighted the need for 
increased clinical evaluation, quality assurance, and quality control of DIR tools.25 Quantifying 
the sensitivity of the DIR algorithms to user-controlled input parameters remains even more 
limited because many implementations function as ‘black-boxes’ in which the user does not have 
the ability to clearly tune the algorithm parameters for specific clinical needs. Without a clear 
understanding of these parameters and their effect on the registration process, large variability in 
DIR accuracy has been noted between institutions, even if they are using the same commercial 
DIR product.53,54 This study aims to provide a comprehensive clinical evaluation of an intensity-
based DIR algorithm and test the effect of the DIR algorithm parameters on quantitative measures 
of registration accuracy.  
Due to the quantity of data and analysis included in this chapter, this chapter is non-
traditionally formatted so that specific methods and materials can be easily referenced while 
reading the results and discussion. An overview section of the methods and materials is provided 
to explain the common elements of the multiple smaller sub-studies. The grouped methods, 
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materials, results, and discussion sections for each of the sub-studies can be separated into two 
primary categories. First we tested and evaluated the DIR algorithm across multiple anatomical 
sites, then we evaluated the sensitivity of the algorithm to parameter inputs on a subset of the 
patients (HN and lung). 
2.3 Methods and Materials Overview 
2.3.1 DIR Algorithm 
In this study, we test and evaluate the intensity-based DIR algorithm found commercially 
in the Velocity software package (Varian Medical System, Palo Alto, CA). Velocity utilizes a B-
spline-based DIR model in which mutual information is used as the intensity-based similarity 
metric to optimize the image transformation. B-spline models are a popular method for 
determining DIR coordinate system transformations due to their ability to capture complex local 
deformations without influencing the global transformation and for their ability to inherently 
produce smooth, continuous DVFs.55 This is attributed to modeling the deformation through sparse 
control points across the image, and then calculating the displacement at any voxel through 
interpolation of the nearby control points. Velocity also incorporates the concept of hierarchical, 
multi-resolution B-spline models, in which the deformation is first calculated with sparse control 
point spacing to resolve larger, global deformations. Then the deformation is refined using denser 
grids of control points to capture small, local deformations. For the intensity-based similarity 
metric, Velocity uses Mattes’s formulation of mutual information, described in detail in Mattes et 
al.56 Briefly, mutual information is calculated by measuring the entropy present in the joint 
probability distribution of voxels sampled between the two image datasets. As entropy is reduced, 
through optimization of the control point displacements, mutual information within the two images 
is increased, signaling more accurate spatial alignment of the images. Since the mutual information 
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metric is based on bins, or groupings, of voxels with similar image intensities, rather than the voxel 
intensities directly, it is possible to calculate meaningful mutual information metrics between 
images of differing modalities (e.g., CT and MR). This is particularly useful in RT, where 
multimodality pre-treatment imaging and daily image guidance has become more prevalent. 
  All registrations were performed in a development/evaluation build of Velocity version 
4.0. Although this specific build includes additional features developed to aid in the evaluation 
process, the underlying DIR algorithm and implementation remains consistent with the clinical 
(commercially available) build of Velocity v3.2 and v4.0. In all cases, an automated rigid 
registration was performed prior to the deformable registration unless both image volumes were 
already in the same frame of reference (e.g., 4DCT). To test the sensitivity of this DIR algorithm 
to changes in the input parameters, a C# application programming interface (API) was jointly 
developed with Varian to provide access to registration parameters that are not currently exposed 
in the commercial user interface. 
2.3.2 Evaluation Metrics 
In this study, two structure-based metrics and one point-based metric were used to assess 
the quality of the DIRs. The structure metric, Dice similarity coefficient (DSC), provides a statistic 
for spatial overlap between two structures and has a range of 0 to 1 (0 = no overlap, 1 = complete 
overlap). In the absence of a manual contour reproducibility study, a DSC of 0.70 is generally 
considered clinically acceptable for moderately sized structures.  Since DSC is dependent, in part, 
on the overall volume of the structure and does not differentiate between overlap of bulk volume 
(at the center of the structure) and overlap at the edge of the structure, the clinically acceptable 
DSC levels should be determined in the context of both the manual contour reproducibility and 
structure size.25 For small structures, DSC becomes increasingly sensitive to minor errors between 
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contours, and therefore, it may be more useful to analyze registrations using the second structure 
metric, mean distance to agreement (MDA).25 MDA provides the average distance between the 
boundaries of two structures.  Generally, a MDA within a few voxels is clinically acceptable.  For 
larger structures (e.g., liver, lungs), the structure-based metrics become less sensitive and it is 
preferable to use the point-based metrics such as target registration error (TRE).25 TRE provides a 
measurement of the residual error within a registration and is calculated by comparing the known 
and transformed locations of stable anatomical landmarks, such as vessel bifurcations. Figure 2.1 
shows visual representations of these three metrics, with the blue representing expected 
transformation result and red representing the registration result. 
 
 
Figure 2.1. Visual representation of the three registration evaluation metrics where blue represents the ground 
truth and red represents DIR prediction. Abbreviations: Dice similarity coefficient (DSC), Mean Distance to 
Agreement (MDA), Target Registration Error (TRE).  
 
2.3.3 Patient Data and Clinical DIR Evaluation 
Anatomized data from four anatomical locations (head and neck (HN), lung, liver and 
pelvis) and multiple imaging modalities (planning CT, CBCT, MRI) were used for the analysis. 
Figure 2.2 shows example images for each of the anatomical and imaging situations considered. 
In the next section, each imaging scenario is described in further detail and is presented in 
proximity to the results and discussion. For each of these scenarios, the Velocity DIR algorithm 
was tested using options broadly available in the clinically released Velocity user interface (UI). 
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Figure 2.2. Example images from the anatomical sites and imaging situations used to evaluate the DIR 
algorithm. Green arrows indicate registrations between planning CT images, blue arrows indicate registrations 
between planning CT and CBCT images, the red arrow indicates registrations between planning MR and CT 
images, and the purple arrow indicates registrations between planning MR images. 
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2.3.4 DIR Parameter Sensitivity Analysis 
 The sensitivity of the DIR algorithm was tested using the HN and lung data from the initial 
clinical DIR Evaluation. This allowed for exploration of registration parameter sensitivity using 
all three quantitative registration evaluation metrics. A linear search for each registration parameter 
was performed, with parameters varied independently when possible. This was done as an attempt 
to determine the individual effect of each parameter on registration accuracy. When not possible, 
such as for number of multiresolution levels and grid spacing, preset values were compared in an 
attempt to determine the registration sensitivity to the joint parameters. Figure 2.3 shows all of the 
parameters available for adjusting in the Velocity C# API, some of which were previously 
adjustable in the UI. For registrations involving a CBCT image volume, the CBCT pre-processing 
filter was applied during the registration process unless otherwise noted. 
 
 
Figure 2.3. DIR algorithm parameters available in the C# API. † Denotes parameter has full adjustability in 




2.4 Methods, Materials, Results, and Discussion (per Sub-Study) 
2.4.1 Head and Neck 
Planning CT - to - Re-Planning CT 
 The registration of head and neck planning CTs is clinically useful for contour propagation 
and mapping doses (planned or accumulated) between treatment plans. Five patients treated at the 
University of Michigan for head and neck cancer were evaluated. Each of the five patients 
underwent mid-treatment re-planning as a result of anatomical changes throughout the patient’s 
treatment course. For each re-plan, a new simulation (planning) CT was acquired and contoured 
for purposes of generating a new clinical treatment plan on the updated patient geometry. This 
allowed for contour-based evaluation of deformations between each patient’s planning CTs. The 
‘Deformable Multi Pass’ option was used for the registration with a manually positioned region-
of-interest (ROI) encompassing all the structures of clinical interest. The quantitative evaluation 
utilized the structure-based metrics, DSC and MDA, for the following 13 normal tissue structures: 
brainstem, right and left cochlea, inferior and superior pharyngeal constrictor muscles, spinal cord, 
spinal canal (cervical region), esophagus, larynx, right (R) and left (L) parotid, right (R) and left 
(L) submandibular (submand) glands. 
 Figure 2.4 shows the evaluation results for this DIR application. In summary, the DIR 
performs consistently well in propagating the brainstem, spinal cord, spinal canal, esophagus, left 
and right parotid glands, and left and right submandibular glands (DSC > 0.7 and MDA < 2.0 mm). 
Small structures, including the cochlea and constrictors, have lower DSC (0.62–0.70), but the 
MDA is within a voxel (1.1–1.5 mm). Overall, these results demonstrate that the Velocity DIR 
algorithm is clinically acceptable in most cases for normal structure propagation between head and 
neck planning CTs. For patients with rapidly responding or growing lesions near organs at risk 
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(particularly of concern for HPV+ patients), the DIR may fail to provide locally accurate 
deformations.  
 
Figure 2.4. DSC and MDA results for DIRs between head and neck planning CTs. Submand* excludes a case 
with rapidly responding lesion near the left submandibular gland. 
 
Planning CT - to - CBCT  
Similar to the previous DIR application, the registration of a cone-beam CT (CBCT) to a 
patient’s planning CTs is clinically useful for tracking patient response over the course of RT and 
for reconstructing delivery dose.  The same five head and neck cancer patients used in the 
previously described evaluation of planning CTs were used for evaluation of deformations 
between planning CTs and daily CBCTs. For each of the five patients, three CBCTs were selected 
with time points spread throughout the treatment course to give a range of deformation magnitudes. 
Each of the selected CBCTs were contoured by a resident radiation oncologist with previous 
experience in head and neck contouring for treatment planning. An intra-observer contour 
variability study was performed since it is not standard clinical practice to contour on CBCTs. For 
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this study, the physician re-contoured five CBCTs (one per patient) in order to gather statistics on 
manual contouring variations. The structure base-statistics, DSC and MDA, from the manual 
contouring were then used as a reference for analyzing the DIR performance. Velocity’s ‘CBCT 
Corrected Deformable’ registration option was used with an ROI placed at the boundary of the 
CBCT image volume. The following normal tissue structures were analyzed using the DSC and 
MDA structure metrics: inferior and superior pharyngeal constrictor muscles, spinal canal 
(cervical region), esophagus, larynx, right and left parotid, right and left submandibular glands. 
Results of the intra-observer contour reproducibility study are shown in Figure 2.5. Based 
on these results, the clinically acceptable levels for the DIR performance were set at DSC ≥ 0.70 
and MDA ≤ 2.0 mm. 
 
Figure 2.5. Intra-observer reproducibility of contouring normal tissue head and neck structures on CBCTs. 
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Results from the DIR evaluation are shown in Figure 2.6. The DIR was found to be 
clinically acceptable for the propagation of spinal canal, larynx and parotid glands (DSC 0.7–0.9) 
and pharyngeal constrictors (MDA < 2 mm). Although the spinal cord was not directly evaluated, 
the cervical region of the spinal canal was accurately propagated which suggests that evaluation 
of accumulated dose to the cord should also be accurate. Evaluation of the esophagus and 
submandibular glands demonstrated unacceptable DIR performance. However, the esophagus 
results should be taken in the context of the relatively large manual contour variation. The reduced 
DIR performance for propagating the submandibular glands is clinically concerning and could be 
caused by the proximity to the lower jaw, especially in the presence of CBCT photon starvation 
artifacts caused by metal implants.  
 
Figure 2.6. DSC and MDA results for DIRs between head and neck planning CTs and CBCTs. The L Submand* 
structure category excludes one patient with rapidly responding lesion in close proximity to the left 





4DCT(Inhale) - to - 4DCT(Exhale)  
 Deformable registration between phases of a 4DCT can be useful in both treatment 
planning and estimation of functional parameters such as ventilation. A publicly available dataset 
(DIR-Lab) was used to evaluate this application of the DIR algorithm.57,58 This dataset has been 
used throughout the image registration research community and often serves as benchmarking data 
for evaluation of new DIR algorithms. This dataset includes 10 cases (5 of which have 256x256 
reduced field of view 4DCTs) with 300 manually selected landmarks on the extreme phases of the 
4DCT. Although these cases offer a range of respiratory motion magnitude (4.0–15.16 mm), it has 
previously been shown that near voxel level DIR accuracy can be achieved across the cohort.  
Initially for this evaluation, the ‘Deformable Multi Pass’ was compared to the ‘Extended 
Deformable Multi Pass’ to determine whether additional multiresolution steps improved the 
registration quality.  These registrations were performed with a manually placed ROI 
encompassing the entire lung and with the ‘Use contrast’ setting turned on. The contrast was set 
at the preset lung value, [−1000, 200 HU]. As the shown in Figure 2.7, ‘Deformable Multi Pass’ 
gave an overall TRE vector of 4.5 mm (SD 2.3 mm), while the ‘Extended Deformable Multi Pass’ 
resulted in a TRE of 3.7 mm (SD 1.8 mm). The slight accuracy improvement with the extended 
option is likely a result of the finer resolution B-spline grids allowing for more flexibility in 
aligning small substructures within the lung. 
 Despite the improvement in registration accuracy when using the extended option, the 
average TRE using the preset contrast settings was determined to be clinically unacceptable on the 
basis of comparison to the known achievable accuracy when using other DIR algorithms. 
However, initial testing of image contrast setting in the UI demonstrated that the algorithm is 
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highly sensitive to this input parameter. For example, the results of using a contrast setting of 
[−1000, −242 HU] are shown in green on Figure 2.7. For these DIRs, the average TRE was found 
to be 2.2 mm (SD 0.2 mm). This demonstrates a significant improvement, but the error remains 
larger than clinically acceptable. It should also be noted that the ribs (chest wall) show residual 
misalignment and non-physical deformations when using these registration contrast settings. 
 
 
Figure 2.7. Mean population TRE for deformable registration of 4DCT extreme phases. 
 
Planning CT - to - CBCT  
 Deformable registration of lung planning CTs to CBCTs was evaluated for the purposes of 
dose accumulation. Ten patients treated for lung cancer at the University of Michigan were 
selected for evaluation. 30 corresponding landmarks were manually selected on the planning CT 
and two CBCTs for each patient. A reproducibility study was performed to determine the error in 
manually selecting these points, and the average error was found to be sub-voxel (0.7 mm TRE 
vector). Therefore, in this evaluation, the goal for residual error following a deformable alignment 
was set at the voxel level (1.7 mm TRE vector). Deformations were performed using the ‘CBCT 
Corrected Deformable’ option with an ROI cropped to the vertical CBCT boundary and the lateral 
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lung boundaries. Although these breath-hold scans had limited respiratory deformation, 
preliminary testing found that multi-pass performed better than the single-pass option. For clinical 
evaluation, the ‘Use Contrast’ setting was turned on and the contrast was set at the lung preset. 
Figure 2.8 shows the TRE results of the deformable registration compared to the rigid registration. 
The deformable registration performs well, giving a mean TRE of 1.8 mm (SD 0.3 mm) with low 
patient variability (1.6–2.2 mm). This demonstrates that the Velocity algorithm is robust and 
provides near voxel level accuracy for this clinical use case.  
 
 
Figure 2.8. Mean population TRE for deformable registration of lung planning CTs to breath-hold CBCTs. 
 
2.4.3 Liver 
Planning MR - to - Planning CT  
The usage of MR imaging in radiation oncology continues to increase through the 
acquisition of pre-treatment MRIs to aid in delineating tumors and, more recently, through MR-
guided RT and functional avoidance treatment planning. Therefore, the ability to accurately 
register MR scans to CTs has become an important clinical use case for multimodality DIR 
algorithms. One common usage of MR imaging is for GTV delineation. Ten liver cancer patients 
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treated at the University of Michigan were used to evaluate the accuracy of the Velocity DIR 
algorithm in aligning pre-treatment MR imaging to a patient’s treatment planning CT. Although 
the specific MR scan sequence varied between patients, all scans were contrast enhanced T1-
weighted VIBE and selected by the Radiation Oncologist at the time of treatment planning for the 
ability to clearly delineate the boundary of the GTV. DIR accuracy was evaluated using TRE 
calculated using 10 manually selected corresponding vessel bifurcations identified on both patient 
scans. A reproducibility study was performed to evaluate the variability in manually selecting these 
landmarks. Based on the reselection of 10 points across the patient cohort, the variability was 
found to be 0.6 mm in-plane and 1.2 mm axially. Since this variability was found to be lower than 
half the average voxel size of the MR (approximately 2x2x3 mm), the voxel size was used as the 
limiting factor in evaluating TRE for these patients. Deformable registration utilized the ‘MR 
Corrected Deformable’ option and an ROI that encompassed the entire liver vertically and 
extended to the abdominal walls laterally. The ‘Use Contrast’ setting was turned off since there is 
not an intuitive value for contrast settings between MR and CT images.  
Figure 2.9 shows the TRE results for this evaluation with a comparison between the 
Velocity automated rigid registration and deformable registration. The rigid registration resulted 
in an overall vector TRE of 4.9 mm (SD 1.9 mm) and the use of DIR did not substantially improve 
accuracy, with a TRE of 4.0 mm (SD 1.1 mm). Only 7 of 10 cases show improvement in TRE 
when using the deformable registration compared to the automated rigid registration, and only 5 
of 10 cases show improvement over the manually-performed, clinically-used rigid registration. It 
should also be noted that one case showed incorrect rotation following rigid registration and 
required manual intervention prior to DIR. These results highlight the need for robust optimization 
of the registration inputs for this important DIR clinical use case. 
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Figure 2.9. Mean population TRE for deformable registration of liver planning CT to planning MR. 
 
2.4.4 Male Pelvis (Prostate) 
Planning CT - to - CBCT 
Deformable registration of daily CBCTs to planning CTs for prostate cancer treatments 
could be useful for the evaluation of delivered doses to organs at risk and target structures. Ten 
prostate cancer patients treated at the University of Michigan were used for this evaluation, with 
three treatment fractions used per patient. The bladder, prostate, rectum, and proximal femurs were 
contoured on each CBCT to allow for structure-based evaluation of the DIR. TRE was also used 
in the evaluation process by manually localizing three implanted RF beacons for each patient. 
Variability in manually selecting the centroid of the beacons was 0.4 mm in-plane and 0.3 mm 
axially. The deformable registrations were performed using the ‘CBCT Corrected Deformable’ 
with an ROI placed at the boundary of the CBCT so that the ROI position could in replicated 
automatically in the future.  
Figure 2.10 shows the TRE results for registration application. The automated rigid 
registration performed prior to the deformable results in a vector TRE of 6.8 mm (SD 5.3 mm), 
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and the DIR gives a TRE of 4.1 mm (SD 3.5 mm). In one case, incorrect rotation within the auto 
rigid initialization caused a patient-specific TRE of 20 mm. This appears to be caused by a large 
bladder volume difference and changes in the spatial relationship between soft tissue and bony 
anatomy. Overall, the large average TRE and standard deviation could be the result of CBCT 
artifacts around the RF beacons. In the absence of post processing tools used to suppress this 
artifacts, using the DIR contrast setting may help to improve registration quality. 
 
 
Figure 2.10. Mean population TRE for deformable registration of prostate planning CT to daily CBCT 
imaging. 
 
Figure 2.11 shows the results of the structured-based evaluation using both DSC and MDA. 
Structure mapping for the femurs is consistently accurate with the average DSC > 0.90 and MDA 
< 2 mm. The bladder contour propagation is generally acceptable (DSC > 0.70) but is dependent 
on bladder volume changes between scans. When the fractional bladder volume change is less than 
0.5, clinically acceptable alignment is achieved, but when the fractional bladder volume change is 
above 0.5, the DIR gives a large range of results (DSC 0.45–0.80).  The average prostate alignment 
is near clinical acceptability (DSC = 0.69), but is also dependent on bladder volume. For cases 
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with large bladder volumes (> 350 cc), the prostate alignment tends to be worse (DSC 0.50–0.70), 
and DIR in these cases results in a large TRE range (1.4–8.4 mm). Structure mapping of the rectum 
was found to be near the clinically acceptable limit with an average DSC of 0.64 (SD 0.06).  
Overall, structure mapping in the presence of moderate bladder volume change is clinically 
acceptable, but the large average implant TRE and inability to accurately map structure boundaries 
in proximity to the prostate (e.g., anterior rectum wall) demonstrate limitations of the current 
algorithm inputs for this application.  
 
 
Figure 2.11. DSC and MDA results for DIRs between prostate planning CT to daily CBCT imaging. 
 
2.4.5 Female Pelvis (Cervical Cancer) 
Planning MR - to - Planning MR 
 Treatment planning for multi-fraction brachytherapy treatments, which is the standard of 
care for cervical cancer, requires significant clinical resources since each fraction requires new 
contours be drawn for daily plan optimization. Usage of a DIR algorithm to accurately propagate 
structures between treatment fractions would improve clinical workflow and decrease time 
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between patient imaging and treatment. To analyze this clinical use case, 10 patients treated at the 
University of Michigan for cervical cancer were evaluated. For each fraction, a T1-weighted MR 
scan was acquired and contoured for the purpose of treatment planning. Each patient was treated 
in five fractions; however, some fractions were excluded from this study on the basis of inadequate 
bladder draining despite use of a Foley catheter during imaging. In total, 43 fractions were used, 
with 33 fractions being analyzed for contour propagation since each patient required a single 
manually contoured fraction. The structure metrics DSC and MDA were used to evaluate the 
quality of the DIR for the following structures: bladder, sigmoid colon, high risk CTV (HRCTV). 
Although contouring on the MR images is standard clinical practice, variability was noticed in 
contouring the rectum and sigmoid.  An intra-observer contour variability study showed that re-
contouring gives an average DSC for the rectum and sigmoid of above 0.80. The MDA for re-
contouring the rectum was 1.8 mm (SD 2.8), but average MDA for the sigmoid was larger at 3.1 
mm (SD 5.1). Since the boundary of the rectum and sigmoid was difficult to determine, the union 
of the two structures (labeled C-S + R) was also analyzed. 
 Preliminary testing showed that the standard ‘MR Corrected Deformable’ registration 
option did not allow for enough deformation in the presence of bowel gas movement and bladder 
volume changes. Therefore, the ‘Deformable Multi Pass’ option was used with the MR fade 
correction manually applied prior to the registration. Although this can lead to highly-variable 
deformation fields that are unsuitable for voxel-based dose accumulation, it allows for improved 
structure propagation. 
 Figure 2.12 shows the results of the structure propagation using the DIR. For the bladder, 
HRCTV, and rectum, the structure propagation is clinically acceptable (DSC > 0.70). Although 
the sigmoid falls below the clinically acceptable limit, the union of the sigmoid and rectum is 
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clinically acceptable. Significant decrease in the HRCTV volume led to poor propagation results 
for the HRCTV in two cases. Similar to the male pelvis use case, the results are dependent on 
bladder volume changes between fractions. When the fractional bladder volume change is less 
than 0.5, clinically acceptable alignment is achieved, but when the fractional bladder volume 
change is above 0.5, the DIR accuracy is highly variable and case dependent (DSC 0.40–0.90).  
However, bladder volume change does not correlate well with the accuracy results of other 
structures. Variability in the results for the sigmoid and rectum appear to be caused by large 
changes in gas volume and spatial distribution.  
Overall, structure mapping is clinically acceptable when using the multi pass deformable 
registration and manually applied MR fade correction. As previously noted, voxel-based dose 
accumulation would require further investigation when using this registration option
 
Figure 2.12. DSC and MDA results for DIRs between female pelvis MR imaging. 
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2.4.6 Image Histogram Limits 
Image histogram limits are the minimum and maximum intensity values used when binning 
intensities together for use in the mutual information metric calculation. These limits, which are 
individually adjustable for each image volume, set the levels of the first and last bins within the 
intensity binning (down sampling) process. Information beyond these cutoffs is not discarded but 
instead grouped into two bins above and below the levels. By default, the algorithm uses the image 
minimum and maximum intensities for the histogram limits. Therefore, we refer to histogram 
limits as not being enabled by default since they are not user-controlled, although they are 
inherently present. 
Although these levels can be individually adjusted for each image volume in a registration, 
this study used the same limits between volumes given that only CT to CT and CT to CBCT 
registrations were performed. This means that two, instead of four, parameters were varied across 
the registrations. A linear search of the parameter space was performed in increments of 250 
starting at level of −1000. 
For head and neck registrations, the histogram limits were varied using the preset 
deformable multipass registration parameters as a basis for other parameters. DSC and MDA were 
visualized as heat maps across all previously noted structures. Figure 2.13 shows an example 
heatmap produced for analysis of these registrations. Each row represents a specific set of 
registration parameters executed over the patient cohort with the population mean DSC and MDA 
reported. Overall, no significant improvement was obtained by adding and adjusting the histogram 
limits. No individual histogram limit pair produced the best registration accuracy across all of the 
analyzed structures. More specifically, although registration results varied across the multiple 
structures, structures near bony anatomy showed differing trends than those surrounded mainly by 
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soft tissue.  It should be noted that the behavior of the registration metrics for the left 
submandibular gland is driven, in part, by a patient with a rapidly responding lesion.  
 
 
Figure 2.13. Example heat map of mean population DSC (left) and MDA (right) results for head and neck CT 
to CBCT registration with varying histogram limits (center). Heat scale represents worse (red) to better (green) 
registration accuracy. 
 
Deformable multipass registration parameters were also used as a basis for analyzing lung 
registrations. TRE was visualized as a 3D plot of TRE with varying histogram limits on the x-y 
plane. Figure 2.14 shows the TRE across all 4DCT registrations. A clear minimum mean 
population TRE of 1.94 mm is found at histogram limits of −1000, −250. The behavior of the 
parameter space for these registrations is relatively smooth compared to that of CT to CBCT 
registrations, shown in Figure 2.15. For CT to CBCT registration, the minimum mean population 
TRE is less pronounced, with histogram limits from −1000, −250 to −1000, +2000 resulting in 
similar TRE. Similar to the 4DCT, the minimum mean TRE of 1.71 mm was found at limits of 
−1000, −250. Overall, lung registrations are extremely sensitive to the histogram limits and using 
 39 
the limits of −1000, −250 results in registrations with near voxel level accuracy for both lung 
registration use cases.  
Overall, adjusting the intensity limits has a significant impact on registrations with clear 
material/tissue type intensity distinctions, such as in the lung registrations. However, in 
registrations with less intensity-distinguished structures, adjusting the histogram limits is less 
helpful in achieving uniform accuracy improvement across multiple structures. In these situations, 
implementing the ability to discard information above or below the cutoff limits could help, 
particularly for soft tissue structures in close proximity to boney anatomy or air. 
 
 
Figure 2.14. 3D visualization of mean population TRE results of lung 4DCT registration.  A minimum TRE of 




Figure 2.15. 3D visualization of mean population TRE results of lung CT to CBCT registration. A minimum 
TRE of 1.7 mm is achieved at a histogram minimum value of −1000 and maximum value of −250. 
 
 
2.4.7 Number of Histogram Bins 
The number of histogram bins defines how much the image intensity is down sampled prior 
to computing the mutual information metric. In general, too few bins can result in a registration 
that is unable to capture the relationship between the two image volumes; whereas too many bins 
can result in increased entropy within the joint histogram which could inhibit the mutual 
information metric from being accurately estimated. Velocity’s default value for this parameter is 
50 bins, with a minimum of 5 bins, as required by using Mattes mutual information. As previously 
noted, these histogram bins are distributed uniformly between the user defined histogram limits. 
Although not tested in this study, a separate number of histogram bins can be used for each B-
spline resolution level. 
 41 
For head and neck registrations, the deformable multipass registration settings were used 
with a varying number of histogram bins from 5 to 75. Figure 2.16 shows the mean population 
DSC and MDA for CT to CT registrations (CT to CBCT registrations behaved similarly). Highly 
variable registration results were found when less than 10 bins were used, with gradually 
improving registration accuracy between 10 and 20 bins. Beyond 20 bins, the registration metrics 
became increasingly stable, with the default of 50 bins residing in this stable region. 
 
 
Figure 2.16. Mean population DSC and MDA of head and neck CT to CT registrations with varying number 
of histogram bins. The default value of 50 bins is located in the maximum DSC and minimum MDA plateau of 
the parameter space. 
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Analysis of lung registrations used the extended deformable multipass settings with the 
same range of bins, 5 to 75. Figure 2.17 shows that for lung 4DCT registrations, accuracy 
drastically improves from 5 to 10 bins and becomes stable after 20 bins. Once again, the default 
of 50 bins resided in this stable region. Lung and CT to CBCT registrations had similar results and 
demonstrated that only slight and variable improvement in accuracy can be achieved by varying 
the number of histogram bins from the default value. Additionally, reducing the number of 
histogram bins was found to have no appreciable impact on registration speed. 
 
 
Figure 2.17. Mean population TRE results of lung 4DCT registration with varying number of histogram bins. 
The default value of 50 bins is located in the minimum TRE plateau of the parameter space. 
 
In this analysis, the DIR algorithm does not appear to be sensitive to the number of 
histogram bins within the range surrounding the default value of 50. Decreasing the number of 
bins below 15 should be avoided, and appropriate values for the parameter appear to range from 
35 to 75 (the maximum value tested). In registration applications involving MR image volumes, 
the number of histogram bins should be retested since the mutual information metric is likely to 
be noisier than the CT to CT and CT to CBCT registrations tested in this study. In the future, non-
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uniform bin spacing may be worth investigating, although this may conflict with the method used 
to estimate the mutual information metric. 
2.4.8 Sampling Rate 
The sampling rate parameter controls the number of spatial samples randomly selected and 
used in the mutual information metric calculation. Generally, as the sampling rate is increased, 
registration results become more accurate at the cost of increased registration computation effort. 
Therefore, in an unsupervised registration environment without timing pressure, the sampling rate 
should be set at the lowest value that does not reduce registration accuracy. However, in a 
supervised environment, registration execution time may become a more important trade-off with 
registration accuracy. By default, Velocity uses a sampling rate of 20% across all registration 
options. In this study, the sampling rate was varied from 10% to 100% in increments of 10% to 
determine the effect on registration accuracy and computation time. All other registration 
parameters were set at the default values. For registrations involving a CBCT image volume, the 
CBCT preprocessing filter was applied. 
Registration of head and neck CT to CBCT and CT to CT image volumes were performed 
using the Deformable Multipass preset parameters. Figure 2.18 shows the results of varying the 
sampling rate on DSC and MDA for head and neck CT to CBCT registrations. Marginal variation 
in DSC and minimal improvement in MDA were found with increasing sampling rate. A slight 
decrease in the variation in registration results across the patient cohort was also noted. Similar 
results were obtained for head and neck CT to CT registrations. Average registration computation 
time, from a sampling rate of 20% to 100%, increased 22% for CT to CBCT registrations and 47% 




Figure 2.18. Mean population DSC and MDA of head and neck CT to CBCT with varying sampling rate. 
Minimal improvement in registration accuracy is noted at higher sampling rates. 
 
For both lung CT to CBCT and 4DCT, the Extended Deformable Multipass preset 
parameters were used. Figure 2.19 shows the results of varying the sampling rate on lung TRE and 
relative computation time, normalized to 50% sampling, for both lung CT to CBCT and 4DCT. 
For CT to CBCT registration, a 11% improvement in TRE can be achieved by increasing the 
sampling rate to 100%, but the computation time almost doubles. For 4DCT registrations, a 19% 
improvement in TRE was found when increasing the sampling rate to 100%, but this corresponds 
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to a tenfold increase in computation time. For both registration cohorts, variation in the individual 
patient TRE was decreased with increasing sampling rate. 
Based on this analysis, when using this DIR algorithm in an unsupervised registration 
environment, the sampling rate should be increased from 20% to 100%. Although this increases 
computational expense, it will lead to a more robust and accurate registration solution, particularly 
for registrations focused on aligning small structures. Additionally, in a dose accumulation 
application requiring voxel to voxel accuracy, rather than just contour matching accuracy, 
including each voxel in the mutual information metric should improve registration confidence at 
the substructure level. 
 
 
Figure 2.19. Mean population TRE and relative registration execution time for deformable registration of lung 
CT to CBCT (left) and 4DCT (right) with varying sampling rate. A slight improvement in TRE can be noted 
with increased computation time at higher sampling rates. 
 
2.4.9 Number of Multiresolution Levels and Grid Spacing 
Multiresolution levels and variable grid spacing parameters function to help the deformable 
registration avoid local maxima in the mutual information metric. Typically, hierarchical 
deformations are performed from coarse to fine grid spacing to aid in finding the best possible 
overall registration. In the Velocity UI, there are three preset values for this: Deformable or single 
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pass (1 resolution level), Deformable Multipass (3 resolution levels), and Extended Deformable 
Multipass (5 resolution levels). For each resolution level in these presets, the number of grid points 
in each direction is the same fixed value regardless of the physical size of the ROI. The number of 
grid points for each of the preset’s resolution levels is (7), (5, 10, 15), and (5, 10, 15, 20, 25), 
respectively. Given the multitude of variability available for these parameters, we initially 
compared the three preset values and then varied the grid spacing in one of the preset options.  
Comparison of the three presets was performed for the head and neck CT to CBCT, lung 
CT to CBCT, and lung 4DCT datasets, using histogram limits of −1000 and +2750 for head and 
neck cases and −1000 and −250 for the lung cases. Figure 2.20 shows the head and neck CT to 
CBCT comparison with an additional test of turning off the CBCT pre-processing filter when using 
the deformable multipass preset. Minimal variation in the evaluation metrics DSC and MDA was 
found between the individual presets, although the deformable Multipass had a slightly better 
overall performance. The CBCT pre-processing filter did not have a large effect on most structures 
with exception of the left submandibular gland in which improved results were found when not 
applying the pre-processing. For both lung datasets, deformable Multipass performed the best with 
the lowest population mean TRE and variation in the population mean.  For lung CT to CBCT 
mean population TREs were 1.8 ± 0.9 mm, 1.7 ± 0.9 mm, 1.9 ± 1.0 m, and for lung 4DCT the were 
2.8 ± 2.4 mm, 1.9 ± 1.5 mm, 2.1 ± 1.6 mm, respectively for each resolution preset. 
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Figure 2.20. Mean population DSC and MDA of head and neck CT to CBCT with the three registration presets. 
Minimal variation in the metrics was noted, although Deformable Multipass had the best overall performance. 
 
The grid spacing parameter was tested using the head and neck CT to CBCT dataset. 
Spacing was varied from x = 1 to x = 10 using the same multiresolution grid scheme of deformable 
multipass preset. This meant that the number of grid points at each level was the same in each 
direction and set as (1x, 2x, 3x), giving multiresolution deformations with the number of grid 
points ranging from (1, 2, 3) to (10, 20, 30). Figure 2.21 shows the results of varying this parameter. 
Using this multiresolution scheme, a grid spacing of (3, 6, 9) gave the best overall result. However, 
changes in the metrics for individual structures did not demonstrate a consistent trend.  
Overall, when comparing the multiresolution presets, switching from a single resolution to 
hierarchal multi-resolution registration scheme did not significantly affect the registration 
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accuracy for either lung or head and neck applications. However, given the slight improvement in 
accuracy and robustness of hierarchal multi-resolution registrations, the option utilizing three 
resolution levels should likely be used. Deviating from the default grid density of (5, 10, 15) is 
unlikely to result in improved registration accuracy but future analysis should be performed on 
adjusting the grid density based on the physical size of the ROI. 
 
Figure 2.21. Mean population DSC and MDA of head and neck CT to CBCT with varying grid spacing. Results 
of changing the spacing depend on the evaluated structure, but in this multiresolution scheme, a spacing of 




2.4.10 Topological Regularization Constraint 
Deformation constraints can be employed within DIR algorithms to limit extreme 
deformations and effectively smooth the deformation field. Commonly used constraints include 
the Jacobian determinant, which is used as a penalization term within the registration optimization 
process. The goal of incorporating this constraint is to create a more robust registration algorithm 
by limiting local volume change and image inversion/folding. Velocity has implemented a 
constraint into their algorithm that performs similarly to a Jacobian penalty without the significant 
computational cost of calculating the Jacobian determinate values across the vector field.59 By 
default, this method is not used in the deformable registration process; however, the API allows 
activation of this method with user-adjustable constraint parameters. 
This feature was tested using the head and neck CT to CBCT registrations with distance-
limiting coefficients ranging from 0 to 0.95 in increments of 0.05. This tunable regularization 
parameter controls the penalization of differences between two adjacent deformation coefficients. 
At a value of 0, this corresponds to a quadratic roughness penalty in which all differences are 
penalized. As the value is increased, non-penalized (or allowable) differences between coefficients 
are also increased, and therefore, the deformation field roughness is penalized less. Although the 
coefficient could be changed independently in each orthogonal direction, the coefficient was only 
adjusted isotopically in this study. Figure 2.22 show the results of applying the regularization 
penalty with all other registration parameters matching the Deformable Multipass preset. Using a 
distance limiting coefficient of above 0.65 results in registrations that do not substantially differ 
from registrations without the regularization. Degradation of registration metrics is noted when 
applying regularization with a distance limiting coefficient below 0.10. However, employing the 
regularization penalty with a distance limiting coefficient between 0.25 and 0.40 results in similar 
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or improved mean registration metrics for most structures, particularly for the left submandibular 
gland which is affected largely by a single patient in the cohort that presented with a rapidly 
responding lesion. Additionally, variation in registration results across the patient cohort are 
noticeably decreased. This suggests that utilizing the regularization penalty with a distance limiting 
coefficient near 0.35 could result in slightly improved registrations. As a potentially more 
important consideration, this could result in a more robust and stable registration algorithm, which 
would be beneficial when deployed in an unsupervised registration process. 
 
 
Figure 2.22. Mean population DSC and MDA of head and neck CT to CBCT with the topological regularization 
penalty applied using varying distance limiting coefficients. Improved registration metrics are noted for most 
structures when using a distance limiting coefficient between 0.25 and 0.4. 
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2.3.11 Optimization Process Parameters 
A limited analysis of the optimization parameters was performed using the head and neck 
CT to CBCT cases. Generally, these parameters affect criteria for initializing and terminating the 
deformation process. This analysis included independently varying the maximum number of 
optimizer iterations, maximum number of consecutive optimizer attempts, minimum step length, 
and maximum step length using the parameters from the deformable multipass preset as a basis. 
The parameters, metric value percentage difference, relaxation factor, and gradient magnitude 
tolerance, were not evaluated in this study. 
The maximum number of optimizer iterations affects the algorithm’s ability achieve 
convergence at the expense of computation time. For the deformable multipass preset option, this 
is set at a value of 30 iterations for each resolution. In this study, the maximum number of optimizer 
iterations was varied from 10 to 100 in increments of 10 and set at the same value for each 
resolution level within a registration. Figure 2.23 shows the results for varying this parameter, 
demonstrating that an increased number of allowable iterations does not necessarily correlate with 
improved accuracy. Overall, no noticeable trend was found when varying this parameter below or 




Figure 2.23. Mean population DSC and MDA of head and neck CT to CBCT with varying the maximum 
number of optimizer iterations. Minor variation in registration accuracy was found but it did not demonstrate 
a consistent trend. 
 
Early termination criteria for the algorithm is controlled through a parameter defining the 
maximum number of consecutive optimizer attempts. This early termination occurs if the mutual 
information metric does not change more than the metric value percentage difference across a 
defined number of optimizer attempts. Varying this parameter from the default value of 10 did not 
change the registration results, demonstrating that the optimization process was not terminating 
early. In an automated registration setting, this observed functionality is likely preferred, as early 




The maximum step length parameter sets the size of the initial step that the regular step 
gradient descent optimizer takes at each resolution within a registration. This step size is then 
decreased using the relaxation factor during the optimization process until the maximum number 
of iterations is reached or the step size falls below the minimum step length. Together, these 
parameters are mainly related to stable convergence of the deformation solution and affect 
robustness of the algorithm to noise in the mutual information metric. In this study, both the 
maximum and minimum step size were varied. Figure 2.24 shows the result of varying the 
maximum step length from 10 to 150. Slight changes in accuracy, particularly in the MDA metric, 
were found at values below 100, with the best overall registrations occurring with values around 
60 to 70. When using a value above 100, accuracy begins to degrade for structures having larger 
known deformations. This demonstrates that decreasing the maximum step size from the default 
value could slightly improve the registration results. Additionally, analysis of the minimum step 
length parameter demonstrated that the algorithm was not sensitive to changes in the minimum 
step length when the value was set below 1. This suggests that the default minimum value of 





Figure 2.24. Mean population DSC and MDA of head and neck CT to CBCT with varying maximum step 
length. Accuracy is relatively invariant, although some structures had degraded accuracy when using a 
maximum step length above 100. 
 
2.5 Conclusions 
The Velocity mutual-information B-Spline DIR algorithm was quantitatively evaluated for 
clinical accuracy across a number of anatomical locations including head and neck, lung, liver, 
and pelvis for clinically relevant imaging modalities. This comprehensive clinical evaluation 
highlights the importance of body site-specific DIR commissioning and quantitative quality 
assurance testing. The current Velocity DIR algorithm fails to provide clinically acceptable 
registration accuracy across some of the evaluated anatomical locations. Clinically acceptable 
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accuracy was achieved for lung CT to CBCT. Near clinically acceptable accuracy was achieved 
for head and neck (CT to CT and CT to CBCT), lung 4DCT, and female pelvis MR to MR. 
Clinically acceptable accuracy was not achieved in liver MR to planning CT and prostate CT to 
CBCT. As expected, large differences in bladder filling challenge the algorithm in male and female 
pelvis images. 
We found that the automated rigid registration, which can be used as the initial image 
transformation prior to the DIR, does not always provide a reasonable starting point for DIR. In 
some cases, this can lead to large errors in the DIR since the algorithm cannot coverage to a 
reasonable DVF solution. Therefore, in an unsupervised DIR environment, such as that required 
for broad clinical use of dose accumulation, errors in both the automated rigid registration and DIR 
must be considered. For manual DIR, the user should verify that the rigid initialization is 
reasonable prior to starting the DIR process. Further studies are required to determine the 
acceptable level of error in the rigid registration for the DIR algorithm to perform well. 
To test DIR registration parameters, a user-developed C# program was created to 
programmatically determine registration parameter sensitivity for the Velocity DIR algorithm 
using the C# API. Through this analysis of registration parameter sensitivity, it was determined 
that a large improvement in registration accuracy could be achieved in lung cases, but only a 
marginal and variable improvement could be achieved for head and neck cases. For unsupervised 
dose accumulation applications of this DIR algorithm, current registration parameter tuning will 
likely not result in clinically acceptable registration accuracy across all anatomical locations. 
However, anatomically-specific tuning does offer slight improvements over default registration 
settings in terms of both accuracy and robustness and should be considered regardless of future 
algorithm development and implementation.  
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2.6 Extensions 
2.6.1 Deformable Image Registration for MRI-based Cervical Cancer Brachytherapy 
In many use cases, DIR functions as a pre-processing step to a downstream in the RT 
workflow. These downstream clinical processes can include treatment planning, dose 
accumulation, and longitudinal image analysis. Each of these potential uses of DIR likely comes 
with different accuracy needs and requirements. As an example, for treatment planning relying on 
DIR-propagated contours, only the boundaries of the propagated structures need to be accurately 
mapped. However, for delivered dose reconstruction and accumulation, voxel-wise accuracy may 
be required. Therefore, a more insightful way to evaluate DIR accuracy is to analyze its impact 
directly in the desired use case. As previously mentioned, brachytherapy is an integral component 
of locally advanced cervical cancer treatment. The field of brachytherapy has recently transitioned 
away from point- to volume-based planning, allowing for improved target and normal tissue 
visualization and more conformal dose delivery with improved OAR sparing and target coverage. 
Although volume-based planning has advantages, daily manual contouring of structures and plan 
adaptation require additional time leading to the risk of intra-fractional anatomic changes and 
increased patient discomfort. To address this challenge, we studied the dosimetric impact of DIR-
based contour propagation on MRI-based cervical cancer brachytherapy planning.60 Through this 
study, we demonstrated that DIR contour mapping could serve as a clinically acceptable 
replacement for manual contouring, providing significant time savings in cases that did not have 
dramatic changes in bladder filling state between fractions. 
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2.6.2 Dose Accumulation Process and Dashboard Development 
Previous studies have exemplified the need for developing an automated workflow that 
could make widespread clinical use of adaptive radiotherapy, including dose accumulation, 
feasible. In part, automation is necessary due to the complexity present in the typical offline 
adaptive workflow, which often requires integration of DIR, dose calculation, and dose summation 
functionality to support clinical decision-making and if indicated, plan adaptation and re-
optimization.9 This process is referred to as offline since the ‘dose-of-the-day’ calculation, in 
addition to dose warping and summation into the same anatomical patient representation, occurs 
after an RT treatment is delivered to the patient. After this process, clinicians can review the 
accumulated dose metrics (i.e., dose delivered to date), which factors in anatomical changes and 
setup errors, and compare it to the planned dose metrics to determine if an intervention in the 
patient’s treatment plan is required due to dose deviations or tissue response. In this method, dose 
could be recalculated using weekly imaging, assuming that anatomical changes occur slowly over 
treatment, or daily imaging, which better accounts for rapid anatomical and physiological changes 
in addition to daily set up errors.153,154 In particular, implementing a daily offline adaptive 
workflow in a clinical setting requires automated processing since steps throughout include time-
consuming computations (e.g., DIR, dose calculation) and data transfers. Additionally, the amount 
of new data generated through the process (e.g., daily dose distribution, daily dose metrics, 
structure volume changes and deformations) would be difficult for clinicians to review for each 
patient on a daily basis and therefore would greatly benefit from an automated analysis step to flag 




 Through a co-development project with Varian Medical Systems, we developed an 
automated offline adaptive workflow, incorporating daily dose accumulation, that utilizes features 
from both Velocity™ and Eclipse™. An overview of the workflow and subcomponents is outlined 
in Figure 2.25. Briefly, Velocity handled the deformable registration and resampling process, 
while Eclipse was used for dose calculation and data storage. These components were contented 
through the newly developed Velocity C# API and existing Eclipse API allowing for data transfer 
between the systems.  
This workflow followed the following process for calculating the daily and accumulated 
dose. First the system is automatically triggered to begin the workflow after a new treatment 
session is completed (i.e., a patient completes a fraction of their treatment course). The planning 
CT and daily volumetric imaging (i.e., CBCT) is then transferred from Eclipse to Velocity, 
wherein an intensity-based B-spline DIR is performed to spatially map the planning CT to the 
CBCT. The DIR transform is then applied to the planning CT to warp the image towards the 
anatomy present on the CBCT which allows for dose calculation on the daily anatomy. Although 
differing methods exist to more efficiently calculate daily dose, we chose to calculate dose on the 
warped planning CT because direct dose calculation on the CBCT suffers from inaccuracies caused 
by the limited field-of-view and image acquisition dependent calibration. Additionally, the 
calculated DIR transform for warping the planning CT to the CBCT facilitates convenient dose 
accumulation from multiple daily dose calculations back to the original planning CT for direct 
comparison with the original, planned dose. The warped planning CT is then transferred back to 
Eclipse where the original treatment plan is copied and the dose is recalculated on the warped CT. 
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Figure 2.25. Workflow for the daily dose accumulation tool that was developed by linking Velocity™ and 
Eclipse™ through scripting interfaces
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transferred back to Velocity where it is transformed back to the anatomy of the original planning 
CT (through inversion of the DIR) and is added to the accumulated dose total. Both the daily 
(fraction) dose distribution and accumulated dose to date is then sent back to Eclipse to allow 
clinicians to review the data if needed. The automated workflow was accompanied with a newly 
developed dashboard, shown in Appendix A, that presented users with the ability to set automated 
dose deviation warning/alert levels in addition to review daily and accumulated dose metrics, 
structure volumes, and trends. Example data from this system, calculated retrospectively for a HN 
cancer patient, is shown in Figure 2.26 and includes the esophagus mean fraction dose (red line, 
scaled to 35 fractions) and the accumulated dose (blue line, also scaled to 35 fractions) tracked 
across all 35 fractions. Although the final accumulated dose is similar to the planned dose, large 
variations in the fraction dose are noted, particularly for fraction 21. After additional analysis, this 
large difference was tracked back to improper patient set up for that treatment fraction. This 
process was successfully used retrospectively across multiple patients without issue; however, 
clinical validation of the process and results was not performed and clinical implementation was 
never achieved. Future implementation of this workflow will require clinical validation of the 
process and API functionality, analysis of error and failure pathways, and determination of 
clinically relevant warning/alert levels. 
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Figure 2.26.  Daily dose accumulation for a HN cancer patient across a 35 fraction treatment course tracking 
esophagus mean dose. 
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Chapter 3  
Characterization and Implementation of Radiation-Induced Dose-Volume 
Liver Response for Biomechanical Deformable Image Registration 
 
Portions of this chapter are substantially equivalent to work the author has already 
published in International Journal of Radiation Oncology Biology Physics.61 
3.1 Abstract 
Understanding anatomical and functional changes in the liver resulting from radiotherapy 
is fundamental to the improvement of normal tissue complication models needed to advance 
personalized medicine.  The ability to link pre-treatment and post-treatment imaging is often 
compromised by significant dose-dependent volumetric changes within the liver that are currently 
not accounted for in deformable image registration (DIR) techniques. This study investigates using 
delivered dose, in combination with other patient factors, to biomechanically model longitudinal 
changes in liver anatomy for follow-up care and re-treatment planning. Population models 
describing the relationship between dose and hepatic volume response were produced using 
retrospective data from 33 patients treated with focal radiation therapy. A DIR technique was 
improved by implementing additional boundary conditions associated with the dose-volume 
response in series with a previously developed biomechanical DIR algorithm. Evaluation of this 
DIR technique was performed on computed tomography imaging from seven patients by 
comparing the model-predicted volumetric change within the liver to the observed change, 
tracking vessel bifurcations (branching points) within the liver through the deformation process, 
then determining target registration error (TRE) between the predicted and identified post-
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treatment bifurcation points. Evaluation of the proposed DIR technique showed that all lobes were 
volumetrically deformed to within the respective contour variability of each lobe. The average 
TRE achieved was 7.3 mm (2.8 mm LR and AP, 5.1 mm SI), with the SI component within the 
average limiting slice thickness (6.0 mm). This represented a significant improvement (Wilcoxon, 
p < 0.01) over the application of the previously published biomechanical DIR algorithm (10.9 
mm). This study demonstrates the feasibility of implementing dose-driven volumetric response in 
deformable registration, enabling improved accuracy of modeling liver anatomy changes, which 
could allow for improved dose accumulation, particularly for patients who require additional liver 
radiotherapy. 
3.2 Introduction 
Liver cancer, including both hepatocellular carcinoma (HCC) and intrahepatic biliary duct 
cancer (cholangiocarcinoma), is the fourth most common cause of cancer-related mortality in the 
United States with an estimated 31,780 cancer deaths in 2019.62 This is one of the few cancer types 
that has undergone a sustained increase in incidence over the past two decades with an average 
annual percentage increase of 2.5% between 2012 and 2016.62-64 Additionally, colorectal cancer 
(CRC) remains one of the most common cancer types globally for both men and women, 
accounting for nearly 1 in 10 cancer cases and deaths.62,65,66 For these patients, the most common 
site to develop metastatic disease is the liver.65 At the time of CRC diagnosis, 20% of patients will 
present with synchronous liver metastases, and an additional 35–50% of patients diagnosed with 
CRC will develop liver metastases as the most prevalent mode of failure within 5 years of initial 
treatment.67,68 
For HCC, biliary, and CRC patients presenting with unresectable liver tumors, radiation 
therapy (RT) provides a nonsurgical focal treatment option and has also been investigated as a 
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bridge to liver transplant for HCC patients.69 However, historically the use of RT for treatment of 
liver tumors has been limited by the tolerance of normal liver tissue to radiation. Prior to recent 
advancements in RT delivery techniques, RT in the liver generally resulted in large volumes of 
normal liver tissue receiving damaging doses of radiation, leading to a high incidence of potentially 
devastating radiation induced liver disease.70 With modern delivery techniques, such as intensity-
modulated RT (IMRT) and daily image guidance, it is now possible to spare a larger percentage 
of the liver from radiation damage while still delivering therapeutic dose levels to the tumor. These 
improvements have led to increased usage of RT for hepatic tumors, particularly for small tumors 
< 5cm, but liver toxicity remains a concern and delivering radiation to larger tumors continues to 
be strongly limited by toxicity. As an example, recent clinical trials involving the use of 
stereotactic body RT (SBRT) for locally advanced HCC were able to achieve high rates of loco-
regional control (87% at 1 year).71 However, the rate of grade 3 or higher toxicities was found to 
be 30%, with 7 patient deaths possibly related to treatment.71 Therefore, there is strong motivation 
to better understand radiation liver toxicity in the era of modern RT delivery techniques in an effort 
to reduce the prevalence of toxicity while maintaining excellent local control. 
Advancements in functional imaging-based assessments, such as positron emission 
tomography (PET) and dynamic contrast enhanced (DCE) MRI, have improved the ability to 
analyze liver function beyond global measures of liver function. Beyond baseline functional 
analysis, the spatially-varying functional information provided by these imaging techniques can 
be incorporated into RT to better tailor the treatment to a specific patient. For example, liver 
function maps can be used in RT plan optimization to guide preferential sparing of certain liver 
regions from radiation in order to minimize a patient’s overall risk of liver toxicity or to maximize 
a patient’s remaining liver function after RT.72,73  Implementing these types of treatment planning 
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methods depends, in part, on the ability to predictively model functional changes to subunits of 
the liver based on the radiation dose received by the subunit.74-77 However, assessment and analysis 
of localized changes in liver function can be hindered by the inability to spatially correlate the 
subvolumes of tissue within the liver.75,76 In addition, significant non-uniform changes in liver 
volume can compromise the correlation of the dose delivered with the longitudinal changes in the 
liver function observed in functional imaging. Figure 3.1 demonstrates the potential magnitude of 
liver changes over the course of RT treatment and the potential anatomical misalignment between 
the pre-treatment (RT-planning) CT image, post-treatment CT image, and post-treatment DCE-
MRI corresponding to liver function. This misalignment, which is driven both by anatomical 
motion and volumetric changes, impairs spatial correlations between the planned-RT dose 
distribution (spatially linked to the planning CT) and functional changes identified in post-
treatment functional imaging.  Improved accuracy in the correlation of functional imaging with 
delivered dose could lead to modifications of currently used liver normal tissue complication 
probability models to better account for the likelihood of spatially localized changes in liver 
function.75,76 
 
Figure 3.1. Pre-treatment (RT-planning) CT image with liver contoured in blue (left), Post-treatment CT image 
of the same patient with the current liver anatomy contoured in red and the blue liver contour copied from the 
pre-treatment CT (middle), Post-treatment DCE-MRI with the blue liver contour copied from the pre-
treatment CT (right). 
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 Furthermore, SBRT is becoming an increasingly favored treatment method for patients 
with unresectable oligometastases in the liver.78-86 Development of additional liver metastases can 
require multiple courses of SBRT, presenting a need to accurately map previously delivered dose 
to the subsequent treatment plan(s) for safe treatment planning. Although current dose mapping 
techniques can accurately account for respiratory and other anatomical motion between treatment 
courses, no current technique directly accounts for potentially significant hypertrophy/atrophy 
volume changes observed following radiation therapy (RT).87 
This complex dose-volume response of normal hepatic tissue has been observed in many 
studies.82-86 Although precise causation remains unknown, it is hypothesized that this atrophy-
hypertrophy radiation response is similar to the response commonly noted following surgical 
resection and other forms of liver treatment or injury.88,89 Despite these observations, currently 
available deformable image registration (DIR) techniques often cannot accurately account for large 
volumetric changes with localized mass loss or gain.90-92 Previously, this has been demonstrated 
on head and neck cases with weight loss or disease progression and prostate cases with large 
deviations in bladder filling.91-93 Studies have also shown that intensity-based DIR algorithms can 
fail in the presence of homogenous contrast (often observed in liver computed tomography (CT) 
images) and large deformations.93-95 Furthermore, many intensity-based DIR algorithms include 
regularization terms to ensure that the deformation field is relatively smooth across an image. 
These regularization methods function to decrease roughness and irregularities within a 
deformation field, but may consequently restrict a deformation from accurately modeling localized 
volume changes.96 Although biomechanical DIR algorithms often provide more physically 
plausible deformation fields in the presence of large volume changes, deformation is primarily 
driven by external organ boundaries (generated from contours) rather than intra-organ anatomy. 
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In the application of liver registration, this can result in inadequate registration of liver subvolumes 
and intrahepatic anatomy even when the external boundary of the liver appears to be accurately 
registered. 
In order to improve the correlation of subvolumes within the liver, this study proposes a 
modified biomechanical modeling method for hepatic tissue including independent dose-volume 
response deformation forces in addition to a previously developed spatially-constrained 
biomechanical DIR algorithm. Briefly, a relationship between dose and volume response, 
mimicking the thermal expansion relationship for non-biological materials, was developed for a 
population of patients using a subset of the total population. A two-step DIR algorithm was 
developed to include this dose-volume response in addition to spatial constraints. Using the 
patients excluded from the development of the population dose-volume response model, the newly 
developed algorithm including dose-volume response in addition to existing spatial constraints 
(Morfeus with Dose Boundary Conditions) was evaluated and compared to a rigid registration 
method and the previously developed spatially constrained DIR algorithm (Morfeus).  
In summary, the purpose of this study is to improve longitudinal liver registration by 
developing a population-based dose-volume response model for normal liver tissue and 
implementing this dose-volume response as additional boundary conditions in series with 
previously developed biomechanical DIR algorithm. Volume- and point-based metrics were used 
to evaluate the performance of the newly developed DIR technique. 
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3.3 Materials and Methods 
3.3.1 Data collection 
 Forty patients previously treated on an Institutional Review Board approved phase II trial 
of dose-escalated liver RT from 1998 to 2005 were retrospectively investigated .97 In this clinical 
trial, previously described in detail,97 patients were treated with conformal high-dose RT (median 
dose was 60.75 Gy) in 1.5 Gy fractions twice daily (BID). Criteria for patient selection in this DIR 
development and evaluation study included having a single unresectable intrahepatic primary 
malignancy, HCC or biliary, or liver metastasis from CRC, with a pre-RT planning CT and follow-
up CT scans at least 49 days post-treatment. Potential effects of respiratory motion were mitigated 
by use of active breathing control and breath-hold CT scans when possible.  
Liver images were previously contoured using stable anatomical landmarks to delineate 
the left lateral and medial segments, right anterior and posterior segments, and caudate lobe.98 The 
gross tumor volume (GTV) was previously defined for clinical treatment planning purposes. 
Figure 3.2 shows pre-treatment liver and tumor segmentation for one of the patients included in 
the study.  The pre- and post-RT volumes as well as mean radiation doses delivered to each 
contoured region were obtained from the treatment planning software (UMPLAN, University of 
Michigan, Ann Arbor, MI). Of the 40 patients selected, seven biliary and CRC patients were 
randomly chosen for accuracy evaluation while the remaining 33 were used to create a population 
model of normal tissue radiation response. HCC patients were not used for accuracy evaluation 
since the limited HCC patient cohort size did not allow enough data for both generation and 
evaluation of the HCC-specific response model. For the seven patients used in accuracy evaluation, 
a radiation oncologist selected vessel bifurcations within the liver on both the pre- and post-
treatment CT scans to allow for calculation of the target registration error (TRE) to evaluate the 
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accuracy of the model. An example vessel bifurcation is depicted in Figure 3.2 on a pre-treatment 
contrast-enhanced CT image. 
 
Figure 3.2. Liver segmentation shown on 2D axial CT slice (left) and 3D volume rendering (right) in the 
perspective indicated by the white arrow. Identified structures include the left lateral (orange), left medial 
(green), right anterior (purple), right posterior (blue), and caudate (yellow), GTV (red), and one example vessel 
bifurcation (orange crosshair). 
 
3.3.2 Liver Response Model 
To generate explicit dose-response deformation forces for hepatic biomechanical 
modeling, termed Dose Boundary Conditions (Dose BCs) within the deformation process, a 
population model was created to relate liver volume response to dose in terms of a linear expansion 
coefficient (𝛼𝛼𝐿𝐿). This methodology was chosen so that the volumetric response could be directly 
modeled using existing thermal expansion tools within commercial finite element modeling (FEM) 
software packages. By substituting dose for temperature change in a standard isotropic thermal 
linear expansion equation, we can utilize standard FEM thermal boundary conditions to achieve a 
direct relationship and mechanical modeling method for volume change as a function of dose. To 
further clarify, this method is used to model the long-term biological-volumetric response (tissue 
atrophy/hypertrophy) and is not using dose as a surrogate for short-term temperature change 
associated with radiation dose deposition. For the 33 patients used in the population model, the 
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linear expansion coefficient was computed for each of the previously defined segments of the liver 
using Equation 3.1 (modified isotropic thermal linear expansion): 
 
 𝛼𝛼𝐿𝐿 =  
𝑉𝑉𝑓𝑓 − 𝑉𝑉𝑖𝑖
3𝑉𝑉𝑖𝑖 𝐷𝐷
 (3.1)  
where 𝑉𝑉𝑓𝑓 is the component’s final volume, as measured on the post-treatment imaging study, 𝑉𝑉𝑖𝑖 is 
the component’s initial volume, as measured on the pre-treatment imaging study, and 𝐷𝐷 is the 
mean absorbed dose of the component (dose replaces temperature change in the standard linear 
expansion equation). A log-logistic sigmoid function (Equation 3.2) was selected to represent the 
data relationship between 𝛼𝛼𝐿𝐿 and 𝐷𝐷 since it captures the mean structure of the data well and is 
similar to formulas used in normal tissue complication probability and tumor control probability 
models. Using a gridded-search, least-squares approach, the sigmoid function was fit to this data 
to get 𝛼𝛼𝐿𝐿 as a function of 𝐷𝐷. Fitting parameters included 𝛼𝛼𝐶𝐶 and 𝛼𝛼𝐹𝐹 representing the linear 
expansion ceiling and floor, respectively, 𝐷𝐷50 representing the dose at 50% of the linear expansion 
range,  and  γ representing the slope at 𝐷𝐷50. For statistical comparison purposes, a corresponding 
linear least-squares fit was also generated. 
 𝛼𝛼𝐿𝐿 = (𝛼𝛼𝐶𝐶 − 𝛼𝛼𝐹𝐹)�
(𝐷𝐷50 𝐷𝐷⁄ )4γ
1 +  (𝐷𝐷50 𝐷𝐷⁄ )4γ
� +  𝛼𝛼𝐹𝐹 (3.2)  
Stratifications of the response model were investigated based on the hypothesis, formulated 
from previous studies, that dose response is correlated to tumor type (as a surrogate for the 
presence of underlying liver disease, e.g., cirrhosis and hepatitis) and spatial location of the 
tumor.89,99-102 To maintain statistical confidence within the stratifications, stratifications were only 
performed in groups that maintained at least 30 samples. The resulting seven stratifications 
included: all patients (HCC/Biliary/CRC), HCC, Biliary, CRC, Biliary/CRC, right lobe 
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Biliary/CRC, left lobe Biliary/CRC. Significance of these stratifications was determined using a 
statistical comparison of the stratified models to the all-inclusive response model based on 
Spearman’s rank correlation coefficients, an assessment of how well the relationship of dose and 
linear expansion coefficient can be described using a monotonic function, and non-linear 
regression analysis from the sigmoid fit compared to a linear regression. 
3.3.3 Liver Deformation 
This study used Morfeus, an in-house-developed biomechanical model-based deformable 
image algorithm, previously described in detail.28 Briefly, two finite element models (FEM), 
representing the pre and post-RT livers, are generated using the CT contours of the complete livers. 
The pre-RT model is then deformed to the post-RT model via guided surface projections 
(HyperMorph, Altair Engineering, Troy MI). This biomechanical modeling technique incorporates 
linear-elastic material properties of liver tissue and GTV, and allows for the incorporation of 
additional boundary conditions within the finite element analysis (FEA). 
In this study, pre-RT liver FEMs were deformed in a two-step process, shown in Figure 
3.3. In Step 1, Dose BCs are applied using thermal expansion to describe the volumetric response 
of the liver to external beam RT (EBRT). In Step 2, surface constraints are applied, as previously 
published, to resolve anatomical deformation due to patient pose and physiological state.28,93 
 72 
 
Figure 3.3. Flow chart of the proposed biomechanical deformable image registration process with the inclusion 
of dose-dependent volumetric response. We first create a biomechanical liver model using the planning 
computed tomography (CT) image.  Using the linear expansion dose-volume population model and the patient’s 
radiation therapy (RT) dose distribution, we assign each tetrahedral element in the model with a linear 
expansion coefficient based on the mean dose to each element (shown prior to Step 1). We then preform a finite 
element analysis (FEA) run, Step 1, to account for dose volume changes (result shown after Step 1). Afterwards, 
we apply Step 2, another FEA run, using surface correlation boundary conditions to spatially align the Step 1 
deformed liver with the liver contour on the follow up CT (result shown after Step 2). 
 
In Step 1, Dose BCs were generated by grouping tetrahedral elements within the FEM into 
1 Gy dose bins by calculating the mean dose received by that tetrahedron from the 3D dose grid 
produced from the commercial treatment planning software (Eclipse (v11), Varian Medical 
Systems). Each 1 Gy dose region was then assigned a single linear expansion coefficient calculated 
from a population-based liver response model. These coefficients were loaded into the FEM pre-
processor as linear thermal expansion coefficients, and the dose delivered to the liver was applied 
as the boundary condition to model the atrophy and hypertrophy observed in the liver. Since the 
population dose-response model is not representative of GTV response, which varies significantly 
between patients due to many factors, tetrahedral elements representing the GTV were given a 
single patient-specific thermal expansion coefficient based on measured volumetric tumor 
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response from the pre-RT to post-RT CT. Therefore, while the assignment of linear expansion 
coefficients to normal liver tissue is non-uniform and based on dose, the assignment of linear 
expansion coefficients to the GTV is uniform (representing an assumption of uniform volumetric 
response of the tumor). 
Surface constraints, for Step 2 of the deformation process, were defined from guided 
surface projections generated after applying the FEA results from Step 1 (Dose BCs) to the FEM. 
The deformation results of this second FEA were applied in addition to the dose constraint analysis 
to spatially align the liver to the anatomical and physiological position of the liver in the follow-
up image. Therefore, the final deformation vector field for complete DIR process is a summation 
of the tetrahedral displacement results of the Step 1 and Step 2 FEAs. 
3.3.4 Characterization of the FEA volumetric response 
 When considering both normal liver tissue response and the tumor response, the total liver 
volume may change by more than 50%. Volume changes of this magnitude exceed the typical use 
case for thermal expansion and contraction modeling in FEA. For example, linear expansion of 
coefficients of many solid metals are on the order of 10−6/°C. Therefore, a 1000°C increase or 
decrease in the temperature results in fractional length changes on the order of 0.1%. For 
biomechanical modeling purposes, the linear expansion coefficients for the liver and tumor are 3 
magnitudes larger. Therefore, at a radiation dose of 50 Gy, the fractional length changes could be 
in the range of 5–10%. These relatively large volumetric changes mean that the liver FEM is prone 
to volumetric locking, particularly when using first-order tetrahedral elements. Volumetric locking 
is related to the unrealistic over-stiffening of elements when the modeled material is nearly 
incompressible (Poisson's ratio nearing 0.5). Since our linear-elastic FEM represents human tissue 
as nearly incompressible with a uniformly assigned Poisson’s ratio of 0.45, our model may be 
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subject to this effect. Additionally, given that the tissue elements are assigned linear expansion 
coefficients based on a spatially varying dose matrix, heterogeneity present in the dose matrix 
could cause neighboring elements to be assigned different coefficients and thermal loads. 
Therefore, we may be attempting to model different levels of volume change between neighboring 
elements. This is particularly true at the interface between elements representing normal tissue and 
elements representing the tumor because the tumor elements are assigned a tumor-specific, 
uniform linear expansion coefficient.  This varying response between bordering elements may 
cause artificial response locking as a result of the shared sides of the neighboring elements 
attempting to respond differently. Given these considerations, we analyzed the volumetric 
response of individual elements within the FEM to the newly added thermal loads and compared 
it to the expected fractional (relative) element volume change. This analysis was performed for 
both a simple 12 tetrahedral element box FEM with a uniformly applied linear expansion 
coefficient and thermal load, and for the full liver FEM with varying coefficients and thermal 
loads. Figure 3.4 shows the expected volumetric response of the individual elements relative to 
dose based on a sigmoid model of the linear expansion coefficient.  
 
Figure 3.4. Expected fractional volumetric change of elements within the FEM (right) based on a sigmoid model 
of the linear expansion coefficient (left). 
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3.3.5 Accuracy Analysis and Comparison 
Both volumetric response comparison and TRE were used to evaluate the accuracy of the 
model for the seven patients not included in the generation of the dose-response model. First, 
following the initial deformation from application of only the Dose BCs (Step 1), the volume of 
each deformed liver segment was compared to its actual post-treatment volume calculated from 
the contoured post-treatment imaging study. This comparison served as an analysis tool to 
determine whether the expansion and contraction generated from the population model accurately 
predicted the known volume change of each segment. Individual segment volume change was 
compared to previously reported intra-observer contouring reproducibility study for a similar liver 
segmentation methodology which gave the following 95% confidence intervals (CIs): left lateral 
segment 45 cc, left medial segment 56 cc, right lobe (superior and posterior) 84 cc, and caudate 
lobe 10 cc.103 The magnitude and relative accuracy of the volumetric modeling was determined 
across three deformation methods: Morfeus, only Dose BCs (Step 1), and Morfeus with Dose BCs. 
Statistical significance of the volumetric modeling techniques was determined using a Wilcoxon 
signed-rank test. 
TRE was calculated using the selected liver bifurcations for three registration methods: 
rigid, Morfeus, and Morfeus with Dose BCs. The bifurcations for the seven patients selected for 
accuracy analysis were selected a second time by the same observer on the follow-up image in 
order to quantify intra-observer variability. Statistical significance for the comparison of TRE 
between registration methods was determined using a Wilcoxon signed-rank test between 




Characteristics for the seven patients excluded from the population response modeling and 
selected for accuracy analysis are shown in Table 3.1. The tumor type, location, and population 
response model used are provided. Due to varying Post-RT CT slice thickness and number of 
selected bifurcation points, the TRE analysis was performed on an individual patient level in 
addition to a population average. 
 
Table 3.1. Characteristics of the seven patients used for evaluation of the population dose-volume response 
models and proposed deformable image registration method. 
 
 
3.4.1 Liver Response Model and Stratifications 
 Table 3.2 gives statistical and curve fitting analysis for the proposed stratifications. All 
stratifications resulted in significant Spearman correlation coefficients suggesting good negative 
correlation between linear expansion coefficient and dose. Stratifications of HCC, CRC, Right 
Lobe Biliary/CRC, and Left Lobe Biliary/CRC provided increased correlation compared to the all-
inclusive model.  In all stratifications, the log-logistic sigmoid fit gave an improved coefficient of 
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determination when compared to a linear fit. Figure 3.5 shows the log-logistic sigmoid best-fit 
curves for each of the proposed stratifications. The seven patient accuracy analysis utilized 
 the Biliary/CRC models. As noted in Table 3.1, for Patients 1 through 5, the location-specific 
stratification models were used since the tumors were confined to a single lobe, and for Patients 6 
and 7, the general Biliary/CRC model was used since the tumors extended over both the right and 
left lobes. Location-specific models were used instead of tumor-specific models since the average 
Spearman correlation coefficients were greater.  
 





Figure 3.5. Log-logistic sigmoid function fits for each of the proposed patient population stratifications.  See 
Table 3.2 for more information on each stratification and statistical curve fitting results. 
 
3.4.2 Characterization of the FEA volumetric response 
Volumetric response resulting from the application of thermal boundary conditions and 
corresponding linear expansions coefficients was analyzed on a small-scale 12 element cubic 
model and full-scale liver model. Figure 3.6 shows the relative error in the volumetric response 
compared to the applied, or planned, volume change for the cubic model. In this model, uniform 
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material properties and thermal loads were applied to the tetrahedral elements and the volume 
change was calculated over the entire cube under varying expansion and contraction levels. For 
applied volume changes within 15%, error in the modeling remained under 1%. However, at 
applied volume changes greater than 30%, modeling error could be larger than 5% for expansion 
and 10% for contraction. At 20% volume change, the error in contraction modeling begins to 
exceed that of the expansion model, which suggests that volume locking of the elements may be 
occurring beyond that response level. At 50% volume contraction, nearly the maximum expected 
volumetric response provided by the liver dose-response models shown in Figure 3.5, the relative 
volume error after FEA was 19%. Independent testing of second-order tetrahedral elements and 
decreasing the assigned Poisson’s ratio did not demonstrate large volume-response modeling 
improvements, with second-order elements causing increased computational complexity and FEA 
solver time. 
 
Figure 3.6. Relative error in the FEA volumetric response for a simple 12 element box model with various 
planned volume changes in the range of the liver-response models. 
 
 Figure 3.7 shows analysis of the FEA volume response for Step 1 of the proposed DIR 
method. Points on the plots represent the individual volumetric response of each tetrahedral 
element included in the model relative to the radiation dose at the centroid of the element. The 
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color of the points varies from blue to yellow based on the distance to the tumor. For both of the 
FEM models shown, these plots match the general expected shape of sigmoid volume response 
originally shown in Figure 3.4. Due to the usage of discrete dose bins for assigning the thermal 
expansion coefficients, the expected response of the elements, shown as black lines in Figure 3.7, 
is not continuous. Within each of these dose bins, a linear fit of the volumetric responses was 
calculated and is shown as a blue line. As expected from the results presented in Figure 3.6, the 
measured volumetric response begins to deviate from the expected response when the relative 
volume change exceeds −0.2. The response of elements representing the tumors shown as pink 
points on the plots and was compared to the expected volume shrinkage with uniformly applied 
linear expansion coefficients based on measured tumor volume change and mean dose. For Patient 
1, the FEA tumor response, shown as a linear fit in gray, closely matches the expected tumor 
response shown as a purple line. However, for Patient 6, the FEA tumor response underrepresents 
the intended volume change by nearly 15%. This provides further evidence of volumetric locking 
in the FEM when large volume changes are applied. For Patient 1, it is also evident that the 
response of normal tissue elements nearby the tumor are impacted by the response assigned to the 
tumor elements. These bordering elements, shown as yellow points given the proximity to the 
tumor, demonstrate a volumetric response that is in-between the expected normal tissue tumor 
element response and tumor element response. 
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Figure 3.7. FEM analysis of tetrahedral element volume changes for Patient 1 (left) and Patient 6 (right) as a 
function of centroid dose compared to the predicted or expected volumetric response used as inputs in the FEA. 
 
3.4.3 Liver Deformation Accuracy Analysis and Comparison 
Volume Analysis and Comparison 
Of the 29 segments modeled, 16 segments underwent volume changes exceeding the 95% CI 
for manual contouring of each segment location. For these 16 segments, the application of only 
Dose BCs resulted in 81% (13/16) of the segments modeled within the 95% CIs, whereas Morfeus 
(e.g., surface boundary conditions only) resulted in 63% (10/16). Application of the complete 
deformation process, Morfeus with Dose BCs, resulted in all (16/16) of the segments modeled to 
within the 95% CIs. This demonstrates that the proposed DIR technique performs volumetric 
modeling to within the variability of manual contouring. 
Across all segments, the application of only Dose BCs resulted in final segment volumes with 
an average signed error of 2.3% (SD = 17.4%) and average absolute error of 14.5% (SD = 9.6%). 
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The average signed and absolute volumetric errors were 20.0% and 32.3%, respectively, for rigid 
registration, 9.8% and 16% for Morfeus, and 0.5% and 9.5% for Morfeus with Dose BCs. The 
application of only Dose BCs showed significant improvement over rigid registration and regular 
Morfeus (Wilcoxon, p < 0.01 and p = 0.03 respectively). The volumetric difference between 
application of only the Dose BCs and Morfeus with Dose BCs was not significant (Wilcoxon, p = 
0.50), demonstrating that the majority of the volumetric change is occurring during the application 
of the Dose BCs, as intended in Step 1 of the deformation process. Tumor response, using a 
uniform linear expansion coefficient calculated for each patient’s specific tumor response, was 
modeled to an average absolute error of 7.3% (6 cc, SD = 9.3%) using the Dose BCs.  
Target Registration Analysis and Comparison 
Average intra-observer variability for bifurcation selection on this seven patient data set, 
which is a limit for achievable TRE, was found to be LR: 0.9±0.2 mm, AP: 0.9±0.3 mm, and SI: 
1.0±1.0 mm, giving a total vector uncertainty of 2.1±1.1 mm. Additionally, since a majority of 
follow-up scans had relatively large slice thicknesses (greater than 3 mm), precise localization of 
bifurcation points was limited axially and in-plane due to partial volume averaging affects.  Figure 
3.8 shows the average TRE vector for individual patients across the three registration methods: 
rigid, Morfeus, and Morfeus with Dose BCs. For all patients, the TRE improved with 
implementation of the Dose BCs.  
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Figure 3.8. Boxplot of the mean patient Target Registration Error (TRE) for each of the three registration 
approaches: Rigid, Morfeus, and Morfeus with Dose Boundary Conditions (Dose BCs). The newly developed 
method, Morfeus with Dose BCs, showed an improvement in overall vector TRE for each of the seven patients 
when compared to rigid and standard Morfeus registrations. 
 
 
Figure 3.9 shows the overall mean TREs for the three registration methods across all 
directions in addition to the overall TRE vector. In each direction, TREs were improved using 
Morfeus with Dose BCs, resulting in overall mean TREs of LR: 2.8±0.4 mm, AP: 2.8±1.0 mm, 
and SI: 5.1±2.4 mm, and giving an overall TRE vector of 7.3±1.3 mm.  This represents a significant 
44% and 30% improvement in the overall TRE vector when using Morfeus with Dose BCs as 




Figure 3.9. Boxplot of the mean overall Target Registration Error (TRE) for each of the three registration 
methods: Rigid, Morfeus, and Morfeus with Dose Boundary Conditions (Dose BCs). The newly developed 
method, Morfeus with Dose BCs, improvements in TRE for each direction and the overall vector when 
compared to rigid and standard Morfeus registrations. 
 
3.5 Discussion and Conclusion 
A biomechanical registration method has been proposed to more accurately model the complex 
liver deformations resulting from EBRT. The proposed DIR algorithm includes a newly developed 
dose-dependent volume response utilizing population-based normal tissue response models and 
modified FEA thermal expansion modeling to represent dose-based volume changes. The dose-
volume response is applied in series with a previously developed spatial alignment biomechanical 
registration algorithm. This modified two-step deformation process has been evaluated for seven 
patients who were treated on the same treatment protocol as the patients used to generate the 
population dose-volume response model. In the future, this DIR technique could be applied to 
differing patient cohorts, such as SBRT patients, by modifying or regenerating the dose-volume 
response models presented in this study. For more modern RT delivery techniques, such as IMRT, 
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new models would likely need to be created to properly represent the presence of increased dose 
heterogeneity and steeper dose gradients across the liver. Additionally, modeling such patient 
cohorts may require additional refinement of the FEA process. Under these conditions, elements 
in the model may be even more prone to locking during the application of volumetric response 
component. To address this, the use of additional FEA steps, modification of the element types, or 
reworking of the material properties may be required. 
Generation of the population dose-dependent volume response model showed a significant 
negative correlation between planned dose and volumetric response of individual liver lobes. Of 
the six proposed population stratifications, four stratifications demonstrated improved negative 
correlation when compared to the all-inclusive population model. Additionally, four of the six 
stratifications demonstrated improved log-logistic curved fitting metrics when compared to the all-
inclusive model. When a stratification did not improve these metrics, the results were similar to 
the baseline model. Future work involving new and refined stratifications, including biological 
factors beyond tumor type and location, will require a larger sample population.  
The proposed registration method, Morfeus with Dose BCs, demonstrated significant 
improvements in both volumetric modeling and TRE. Volumetric analysis of individual lobes 
showed that this deformation method successfully modeled all lobes within the respective contour 
variability of each lobe. The average TRE achieved with the proposed method was 7.3 mm (2.8 
mm LR and AP, 5.1 mm SI), representing a significant 30% improvement over the previously 
published biomechanical registration algorithm (Morfeus).  
Remaining error in the overall TRE vector is largely due to the residual error in the SI direction, 
which should be taken in the context of relatively large slice thicknesses on post-treatment scans, 
up to 10 mm (shown in Table 3.1). This error measurement could be improved when applying this 
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registration method to scans with improved slice thickness, in part because the reproducibility of 
manually selecting bifurcation points is dependent on slice thickness. Additionally, the modeling 
of the complex deformations observed in the liver might be improved by using corresponding 
vessel positions on the two CT scans as additional boundary conditions in the biomechanical 
model, as previously demonstrated in the lung.104 However, this would rely on high-quality CT 
image contrast enabling visualization of vessels and the assumption of vessel preservation, which 
may not be a good assumption in the presence of large tumor response or cases of tumor induced 
thrombosis. 
In this study, the development and evaluation of a population-based normal liver tissue dose-
response model and application of the dose-volume response within a biomechanical DIR 
algorithm is reported. The use of the proposed liver registration algorithm is feasible and may aid 
in future studies investigating improvement in the accuracy of biomechanical deformable 
registration algorithms. This work has the potential for clinical impact in improving the correlation 
of functional imaging with delivered dose and enabling accurate longitudinal mapping of 
previously delivered doses to planning images for subsequent treatments.  Furthermore, the 
methodology of the proposed DIR algorithm could be used to improve registration in other 
treatment locations in which structures undergo dramatic volume changes as a result of radiation, 






 Normal tissue toxicities remain a major concern when treating patients with RT for head 
and neck cancer. Of these toxicities, xerostomia (dry mouth resulting from a reduction in saliva 
flow) remains prevalent and can lead to diminished quality of life after treatment.105 Current 
clinical practice relies on a correlation of mean parotid gland dose to xerostomia for treatment 
planning; however, small animal studies have demonstrated that doses to sub-volumes of the 
parotid gland may be more predictive of this toxicity.106 In the presence of patient weight loss, 
tumor shrinkage, and parotid gland volume changes during RT, improved DIR is required to more 
accurately correlate patient toxicity to the delivered dose to sub-volumes of the parotid. To address 
this, we applied similar dose-volume response modeling to the parotid gland for head and neck 
deformable registration. McCulloch et al. demonstrated that this approach significantly decreased 
the spatial registration error of biomechanical DIR of the parotid gland and that the improved 
registration accuracy could lead to meaningful differences in the estimated delivered dose when 
compared to a standard biomechanical method.107 However, in order to determine the potential 
impact of these differences on current xerostomia toxicity models, this modeling method would 




Chapter 4  
Incorporation of Patient-Specific Efficacy and Toxicity Estimates in Radiation 
Therapy Plan Optimization  
 
Portions of this chapter are substantially equivalent to work the author has submitted for 
publication to Medical Physics. 
4.1 Abstract 
Current radiation therapy (RT) treatment planning relies mainly on pre-defined dose-based 
objectives and constraints to develop plans that aim to control disease while limiting damage to 
normal tissues during treatment. These objectives and constraints are generally population-based, 
in that they are developed from the aggregate response of a broad patient population to radiation. 
However, correlations of new biologic markers and patient-specific factors to treatment efficacy 
and toxicity provide the opportunity to further stratify patient populations and develop a more 
individualized approach to RT planning. We introduce a novel intensity-modulated radiation 
therapy (IMRT) optimization strategy that directly incorporates patient-specific dose response 
models into the planning process. In this strategy, we integrate the concept of utility-based 
planning where the optimization objective is to maximize the predicted value of overall treatment 
utility, defined by the probability of efficacy (e.g., local control) minus the weighted sum of 
toxicity probabilities. To demonstrate the feasibility of the approach, we applied the strategy to 
treatment planning for non-small cell lung cancer (NSCLC) patients. We developed a prioritized 
approach to patient-specific IMRT planning. Using a commercial treatment planning system 
(TPS), we calculate dose based on an influence matrix of beamlet-dose contributions to regions-
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of-interest. Then, outside of the TPS, we hierarchically solve two optimization problems to 
generate optimal beamlet weights that can then be imported back to the TPS.   The first 
optimization problem maximizes a patient’s overall plan utility subject to typical clinical dose 
constraints. In this process, we facilitate direct optimization of efficacy and toxicity trade-off based 
on individualized dose-response models. After optimal utility is determined, we solve a secondary 
optimization problem that minimizes a conventional dose-based objective subject to the same 
clinical dose constraints as the first stage but with the addition of a constraint to maintain the 
optimal utility from the first optimization solution. We tested this method by retrospectively 
generating plans for five previously treated NSCLC patients and comparing the prioritized utility 
plans to conventional plans optimized with only dose metric objectives. To define a plan utility 
function for each patient, we utilized previously published correlations of dose to local control and 
grade 3–5 toxicities that include patient age, stage, microRNA levels, and cytokine levels, among 
other clinical factors. The proposed optimization approach successfully generated RT plans for 
five NSCLC patients that improve overall plan utility based on personalized efficacy and toxicity 
models while accounting for clinical dose constraints. Prioritized utility plans demonstrated the 
largest average improvement in local control (16.6%) when compared to plans generated with 
conventional planning objectives. However, for some patients the utility-based plans resulted in 
similar local control estimates with decreased estimated toxicity. The proposed optimization 
approach, where the maximization of a patient’s RT plan utility is prioritized over the minimization 
of standardized dose metrics, has the potential to improve treatment outcomes by directly 
accounting for variability within a patient population. The implementation of the utility-based 
objective function offers an intuitive approach to biological optimization in which planning trade-
offs are explicitly optimized. 
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4.2 Introduction 
Advances in radiation therapy (RT) planning and delivery techniques have led to improved 
outcomes for cancer patients, both in terms of increased control rates and decreased treatment 
toxicity.108-110 However, balancing disease control with adverse therapy effects continues to be a 
challenge in RT and across many other cancer treatment modalities. In external beam RT, this 
trade-off is inherent because delivery of radiation to the tumor often requires the use of beam 
trajectories that traverse adjacent normal tissue structures prior to and after converging on the 
target. Consequently, providing a sufficient therapeutic dose to the tumor may result in radiation-
induced normal tissue toxicities, which can negatively impact a patient’s quality-of-life during and 
after treatment. Modern RT techniques, such as intensity-modulated radiation therapy (IMRT), 
have made it possible to deliver highly non-uniform dose distributions with steep dose gradients 
between target locations and organs-at-risk (OARs). While this has enabled improved OAR 
sparing, optimizing an RT plan to best balance the individualized potential for disease progression 
and treatment toxicities remains hindered by conventional dose-metric-based planning techniques. 
Conventional RT treatment planning attempts to address these trade-offs by optimizing 
radiation delivery based on predefined dose-based objectives that have either been previously 
correlated with measures of control and toxicity or determined from expert consensus and 
institutional standards. In inverse IMRT treatment planning, these surrogates of biological 
response are often incorporated into a single objective function through individually weighted 
linear or quadratic penalties, and the fluence map is optimized to minimize the sum of these 
penalties.35 During this process, treatment guidelines and acceptable clinical trade-offs are 
implicitly translated and incorporated into the optimization objective by adjusting the relative 
importance of each dose-based penalty, relying heavily on the planner’s experience and expertise 
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to guide the process.111  Although a substantial amount of research has focused on weight selection 
to improve plan quality,112-120 this optimization approach is limited by the inability to directly 
include individualized, quantitative estimates of the biological outcomes in the optimization 
process. 
Recently, advancements in optimization approaches and availability of commercial 
products for biological optimization have facilitated the move beyond conventional dosimetric 
planning, allowing for the inclusion of tumor control probability (TCP) and normal tissue toxicity 
probability (NTCP) models in the plan optimization process.37 Although implementations of 
available biological optimization methods differ, they are generally restricted in the ability to use 
both estimated biological response objectives and conventional dose-based objectives to drive the 
optimization process.37,121,122 Instead, dose-based objectives may only be regarded as hard 
constraints in the optimization process, potentially limiting the ability to decrease dose to OARs 
with undefined biological response objectives.37,121,122 Additionally, these systems continue to rely 
on aggregated response models and do not account for patient-to-patient variability in tissue 
radiosensitivity.  Recent studies have focused on addressing this through the inclusion of 
personalized models in the planning process.123-126 While these studies have demonstrated the 
ability to optimize treatments based on patient-specific outcome predictions, they remain limited 
to three-dimensional conformal radiotherapy (3DCRT) optimizing the beam angles and 
monitoring units123-125 or prescription.126 Additionally, these methods do not explicitly incorporate 
currently accepted clinical dose constraints which may impede clinical acceptance or diminish the 
realized benefit of the planning strategies. 
To overcome these limitations, we propose an IMRT optimization method, termed 
Prioritized Utility Optimization (PUO), that augments the traditional dosimetric inverse treatment 
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planning process by directly incorporating quantitative estimates of personalized biological 
response while maintaining current dose-based planning objectives. This builds upon previous 
work that introduced the concept of utility-based planning, in which individualized optimal dose 
was selected by maximizing plan utility defined by a weighted combination of predicted efficacy 
and toxicity probabilities.127,128 These studies demonstrated the ability of utility-based planning to 
increase efficacy while maintaining or reducing toxicity levels in a population, but were limited to 
scaling of fixed dose distributions. In the proposed IMRT optimization approach, we translate this 
methodology into a constrained hierarchical optimization problem that prioritizes maximization of 
plan utility over minimization of typical dose metrics and is subject to clinical hard constraints 
throughout. Through this approach, we add the ability to redistribute dose and aim to further 
exploit predictive models of efficacy and toxicity based on biological markers, clinical factors, and 
patient demographics, to improve the personalization of planning trade-offs. In this study, we 
introduce and evaluate the feasibility of the proposed method by applying it to a cohort of 
previously treated non-small cell lung cancer (NSCLC) patients.  
4.3 Materials and Methods 
4.3.1 Optimization Overview 
Our proposed approach utilizes a two-stage optimization process to first maximize plan 
utility and then minimize dose-based metrics. Figure 4.1 provides the mathematical formulation 
of the optimization problems and Table 4.1 provides a full description of the notation used in 
defining the problems. In Stage 1, the objective is to maximize plan utility defined by the predicted 
efficacy probability based on target dose, minus the weighted sum of predicted toxicity 
probabilities across multiple OARs based on respective OAR doses. The efficacy and toxicity 
models are assumed to be monotonic functions of a dose metric, with increasing dose to the 
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structure never decreasing the predicted probability of the event occurring to that structure. The 
weighting parameter for each toxicity, θ, represents the undesirability of toxicity relative to the 
efficacy measure and can be adjusted based upon physician and/or patient preference, or tuned to 
result in an acceptable rate of predicted toxicity across a patient population.128 
 
 





Table 4.1. Optimization notation glossary. 
 
 
The maximization of plan utility in Stage 1 is subject to inviolable clinical criteria for the 
plan, guaranteeing that any solution meets dose-based hard constraints (1b–1f). These constraints 
are based on the following three rationales. First, for any individual patient, increasing predicted 
efficacy can only occur by increasing dose to the target. Since a single target dose metric is used 
to predict efficacy, maximization of utility through increasing efficacy may result in unacceptable 
target dose heterogeneity. This has previously been noted as a potential issue in biological 
optimization methods and is addressed through constraint (1b).37 Second, it is possible that optimal 
solutions exist at dose values above or below levels that physicians would be comfortable 
prescribing. Hard constraints (1c) and (1d) are used to avoid these solutions and avoid 
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extrapolating model predictions to dose values beyond those in the dataset used to fit the models. 
Lastly, it is unlikely that every dose-limiting OAR will have a toxicity model corresponding to 
every dose metric typically used to limit OAR doses during planning. Therefore, constraints (1d–
1f) are included to ensure that any solution meets or exceeds traditional OAR dose limits. To avoid 
non-convex functions of dose, dose-volume constraints (DVC), which are typically represented by 
value-at-risk (VaR) metrics (e.g., V20Gy, D0.1cc), are instead represented by upper conditional value-
at risk (CVaR+) metrics in constraint (1f). CVaR+ represents a convex DVC that captures the mean 
upper-tail dose of a structure’s dose-volume histogram and has previously been used to formulate 
linear RT optimization problems.129-131 Figure 4.2 shows a visualization of both VaR and CVaR+ 
on an example OAR dose-volume histogram (DVH). For a given VaR metric, calculated over the 
volume Vmetric, the corresponding CVaR+ metric is expected to be higher because VaR captures 
the minimum dose and CVaR+ captures the mean dose.  
 
Figure 4.2. Visualization of VaR and CVaR+ on an example DVH with the relevant OAR region for calculation 
of the metrics shaded. 
 
In Stage 2, the objective is to minimize dose-based metrics similar to traditional plan 
optimization approaches. Since Stage 1 effectively only optimizes the OAR dose metrics used in 
toxicity models for the utility function, OAR dose metrics not used in the toxicity models can still 
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potentially be reduced. Therefore, Stage 2 can be considered a solution “clean-up” or refinement 
step, in which all OAR doses are reduced while attempting to maintain the optimal plan utility 
from Stage 1. For computational efficiency, the objective function is a sum of linearized equivalent 
uniform dose (ℓEUD). ℓEUD is a convex piecewise-linear (PWL) approximation of generalized 
equivalent uniform dose and is calculated as a linear weighted combination of the mean and 
maximum doses for a structure.132 In this formulation, the structure-specific parameter α defines 
the importance of max dose and mean dose, ranging from 0 to 1. Constraints (2a–2f) are simply 
carried over from constraints (1a–1f) in Stage 1. However, a new constraint, (2g), is added to 
preserve the optimal plan utility from Stage 1. This constraint allows for relaxation of the Stage-1 
plan utility value to allow sufficient search space for the Stage-2 optimization to reduce OAR 
doses. The relaxation parameter, η, determines the allowable plan utility degradation between 
Stage 1 and Stage 2. Although a value of 1 is ideal (maintaining the optimal utility found in Stage 
1), in practice a value slightly less than 1 may be required to provide the optimization algorithm 
sufficient search space to improve dose metrics in Stage 2. 
4.3.2 Technical Implementation 
Optimization first requires calculation of an influence matrix, A, which represents the dose 
contribution of a discretized beam to a set of voxels or points within a patient volume. To facilitate 
this process, we built a plugin using a research version of the Eclipse Scripting Application 
Program Interface (ESAPI v15.5) (Varian Medical System Inc., Palo Alto, CA) to allow 
integration of our process with our commercial Eclipse treatment planning system (TPS). 
Integration with the TPS provided access to patient images, structures, beam configuration, and 
dose calculation as needed throughout the planning process. Point clouds were generated using 
pseudorandom point sampling of pre-defined structures within a patient’s body with adjustable 
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structure-specific point spacing. Multi-field IMRT plans were configured using pre-defined beam 
angle templates that were initially fit to the target structure(s) and then expanded to create a beam 
that could be divided into uniform beamlet sizes. To calculate the influence matrix, we used an 
ESAPI method (CalculateInfluenceMatrixToMemory()) that separates a beam into beamlets based 
on a user-defined size parameter, typically 0.5 cm or 1 cm based on the target size, and calculates 
a full-scatter influence matrix using the Analytical Anisotropic Algorithm (AAA v15.5.11) (Varian 
Medical System Inc., Palo Alto, CA). Given the size of the influence matrix, the data is then 
serialized using Google’s Protocol Buffers for efficient transfer of the data to the optimization 
system. To reduce the overall size and complexity (i.e., number of variables and constraints) of 
the optimization problems, this clinically accurate influence matrix calculation was separated into 
primary and secondary dose contributions. Secondary dose contributions, consisting of low-dose 
scatter components, were removed from the influence matrix and summed for each point 
separately across each beam. The limit for these low-dose components was empirically determined 
by testing the impact of different limits on the optimization process. A limit of 0.001 Gy/100 MU 
was found to have marginal impact on the optimization results and resulting dose distributions. 
These contributions were then incorporated into the optimization dose estimation by multiplying 
the total low-dose component for each beam by the corresponding average beam fluence. 
Additionally, if the summed secondary contribution for a beam-point pair was found to be less 
than 0.0001 Gy/100 MU, the component was ignored since it is negligible in the context of primary 
dose contributions. The decision variables in the optimization problem were beamlet fluence 
intensities, x, and were forced to be non-negative with constraints (1a) and (2a). 
Maximization of the utility function (f1) requires that the efficacy model is concave relative 
to dose, and the toxicity models are convex relative to dose, within the relevant prediction range. 
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Although predictive models of efficacy and toxicity could take on many non-linear forms, they are 
typically represented by sigmoidal functions of dose (e.g., NTCP and TCP). Methods exist for 
transforming these types of partially convex and concave functions into purely convex or concave 
functions for the purposes of optimization and are useful in determining Pareto efficient 
solutions.133-135 However, these transforms, including log transformations, obscure the relative 
importance of absolute changes in efficacy and toxicity in a weighted-sum approach and do not 
preserve the interpretability of the utility function and weights (θ’s). Therefore, PWL relaxations 
of these models were implemented for the Stage-1 objective function and for constraint (2g) in 
Stage 2, reducing the problems to linear programs which can be efficiently solved with off-the-
shelf commercial optimization solvers. These PWL approximations were uniformly spaced 
throughout the convex or concave envelope of the dose response function with extensions beyond 
the envelope acceptable within the maximum allowable error of 0.5% (absolute). Additionally, 
since many predictive models are based on biological dose, rather than physical dose, we 
implemented the ability for models to be based on equivalent dose in 2 Gy fractions (EQD2) using 
PWL approximations for OARs and linear scaling for target volumes with approximation errors 
less than 1 Gy (EQD2) over the relevant dose range. To eliminate approximation errors during plan 
evaluation, plan utility and individual components of the utility function were recalculated after 
optimization using the original functions. The resulting linear optimization problems were solved 
using a third-party commercial optimization solver Gurobi v9.0.3 (Gurobi Optimization, LLC, 
Beaverton, OR) through the .NET interface on a workstation with dual Intel Xeon E5-2620 v4 8-
core processors and 64 GB of memory. We tested both the simplex and barrier (interior point) 
algorithms implemented in Gurobi to determine which method was more suitable for this set of 
optimization problems. 
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Following optimization, the optimal fluence map can be directly imported into the TPS 
using ESAPI, allowing for leaf sequencing, final dose calculation, and plan visualization. Since 
our optimization process does not include a fluence smoothing stage or intermediate full dose 
calculation, dose discrepancies after leaf sequencing and final dose calculation are expected but 
are not the focus of this initial feasibility study. Therefore, quantitative plan comparisons for this 
study are limited to optimization solutions prior to these steps when possible. 
4.3.3 Retrospective planning study 
For this initial demonstration of the proposed optimization strategy, five previously treated 
NSCLC patients were selected for retrospective treatment planning and plan comparison. These 
patients were selected to be representative of the variation in patient geometry, target size, and 
model inputs from a cohort of 125 stage II-III NSCLC patients previously treated on institution 
review board-approved prospective studies. Table 4.2 provides details for the five patients. All 
patients were treated with definitive standard or dose-escalated 3DCRT with or without sequential 
or concurrent chemotherapy. These studies included data collection previously used to generate 
predictive models of local regional progression-free survival at 2 years (LRPFS2y),136 grade ≥ 3 
cardiac event within 2 years (CE3+,2y),137 grade ≥ 3 radiation esophagitis (RE3+),138 grade ≥ 3 
radiation-induced lung toxicity (RILT3+)139 based on patient demographics, clinical factors, and 
biomarkers. We used these previously published models, further described in Table 4.3, to generate 
personalized predictive dose response curves, shown in Figure 4.3. These patient-specific 
predictions are utilized in Stage 1 of the PUO process for optimization and calculation of overall 
plan utility, as well as constraint (2g) of Stage 2. For this initial study, θ values were uniformly set 
to 1, representing equal pair-wise trade-off between efficacy and each toxicity in the utility 
function. To avoid use of a non-convex DVC in the optimization process, max dose was used in 
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place of D2cc for the esophagus model, leading to slight over-estimation of RE3+ during 
optimization (typically < 0.5%, absolute). However, utility values for plan evaluation were 
calculated using D2cc for the RE3+ prediction. 
Table 4.2. Patient characteristics and overall plan utility metrics. 
 
 




IMRT plans using the PUO approach were generated for the five patients. These 30 fraction 
plans consisted of 8 non-opposing treatment fields placed at standardized beam angles based on 
target laterality. For the influence matrix calculation, beamlets were set to a size of 0.5 x 0.5 cm 
except for patient 5 which required 1.0 x 1.0 cm beamlets due to the large planning target volume 
(PTV) volume and computational limitations.  
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Figure 4.3. Predictive efficacy and toxicity models used to estimate overall plan utility (top left: LRPFS2y, top 
right: CE3+, bottom left: RE3+, bottom right: RILT3+).  All cases included in the generation of the models are 
plotted with gray solid lines while the five cases used for plan comparison are plotted with colored dashed lines. 
White background areas represent the model ranges used in study, whereas the gray background represents 
ranges excluded by hard constraints during optimization. The CE3+ model only stratifies into two distinct 
groups since it is based on one binary covariate, baseline cardiac disease, with heart dose. 
 
Structure constraints used in the optimization are shown in Table 4.4. CVaR+ constraints 
were added as convex representations of the VaR-based DVCs used clinically at our institution, 
including lung-GTV V20Gy ≤ 35%, heart V30Gy ≤ 50%, and heart V50Gy ≤ 25%. These constraints 
were tuned based on a fit of CVaR+ to the corresponding VaR metric based on a retrospective 
analysis of IMRT plans from a separate cohort of 30 previously treated NSCLC patients. Figure 
4.4 shows the correlation of CVaR+ metrics to the corresponding VaR metrics. Given that the 
clinical VaR limits are stated as the percentage structure volume receiving at least a certain dose, 
the limit for CVaR+ constraints was based on the relationship of VaR to CVaR+ at the percentage 
structure volume limits. For the heart, VaR limits exceeded range of data available, so CVaR+ were 
set conservatively based on the maximum VaR percentage structure volumes in the dataset. This 
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relationship is indicated as a red dashed line in Figure 4.4 and the new CVaR+ constraints are listed 
in Table 4.4. Additionally, a CVaR+ constraint for the esophagus was added as a conservative 
representation of D2cc < 68 Gy. VaR dose metrics were checked after plan optimization to ensure 
that plans remained within the original VaR clinical limits. ℓEUD weighting factors were set to 
0.5 for all structures with equal weighting between structures for the Stage-2 objective. Based on 
empirical testing, η was set to 0.999 (0.1% overall utility loss acceptable), constraining Stage 2 to 
retain nearly the same overall plan utility as Stage 1 while still providing the optimization 
algorithm sufficient search space. 





Figure 4.4. Clinical VaR (DVH) metrics and the corresponding CVaR+ metrics for 30 NSCLC patients 
previously treated with IMRT. 
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4.3.4 Planning Comparison 
The proposed PUO method was compared to the clinically delivered 3DCRT plans and 
retrospectively generated dose-only optimization (DOO) IMRT, and volumetric modulated arc 
therapy (VMAT) plans. DOO plans were generated to represent plans with the same beam angles 
and hard constraints as the PUO plans but optimized with only a typical dose metric based 
objective.  These plans were created using a similar workflow as the PUO plans, but only used 
Stage 2 of the PUO process and excluded the utility constraint (2g). An additional constraint for 
minimum target dose of 60 Gy (30 fractions) was added to produce plans that followed current 
clinical planning prescription guidelines. VMAT plans with a 60 Gy (30 fractions) target dose goal 
were generated in Eclipse by a dosimetrist with prior experience in clinical lung treatment 
planning. These VMAT plans were used as a modern, clinically deliverable benchmark for the 
DOO IMRT plans generated with our external optimization process and fixed beam angles. To 
provide a uniform comparison between planning methods, VMAT plans were normalized to the 
D95% of the corresponding DOO plans (normalization values < 102%). 3DCRT, VMAT, DOO, and 
PUO plans were compared by calculating the final plan utility. DVHs of DOO and PUO plans 
directly from the optimal solutions were also compared. Additionally, results from Stage 1 of the 
optimization process without clinical OAR hard constraints(1c–1f), labeled PUOS1,mod, were 
compared to the final PUO utility results to determine what effect, if any, the inclusion of OAR 
hard constraints had on the maximum achievable plan utility. Utility results are compared in terms 
of absolute utility difference. Therefore, given θ values of 1, any change in plan utility directly 
corresponds to a combination of changes in the predicted absolute probabilities of efficacy and 
toxicity. For example, if the predicted probability of efficacy increases by 5% (absolute, e.g., 
changing from 55% to 60% efficacy) with predicted toxicity remaining the same, then the overall 
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utility improvement would be 0.05. Alternatively, if the same increase in efficacy occurs, but one 
of the predicted toxicity probabilities increases by 7% (absolute), then the overall utility change 
would be 0.05−0.07 = −0.02. 
4.4 Results 
For all five NSCLC cases, our approach successfully generated optimal beamlet weights 
that maximize utility while remaining within dose-based constraints. Total (Stage 1 and Stage 2) 
solution times ranged from 16 to 71 minutes, with the number of beamlets and points in the 
optimization problems ranging from 1144 to 2610 and 41888 to 96523, respectively. On average, 
78% of solver time was spent on Stage 2, of which 67% (or 52% of the total solve time) was spent 
specifically in crossover to produce a basic solution.  For our linear problems, Gurobi’s barrier 
method was found to be faster than primal and dual simplex methods but required modification of 
the numerical focus to the maximum setting (NumericFocus = 3) and decreasing the barrier 
convergence tolerance to 1e−5 to reduce crossover solver time. 
Plan utility values and target D95% values (representative of the prescription dose) for the 
various planning methods are shown in Table 4.2 with a further breakdown of the utility metrics 
shown in Figure 4.5. The PUO method resulted in an average absolute utility improvement of 0.21 
(range: 0.09–0.43), 0.17 (0.05–0.31), 0.16 (0.07–0.30) when compared to 3DCRT, VMAT, and 
DOO plans, respectively. DOO IMRT plans were shown to have similar utility to VMAT plans, 
demonstrating that the DOO plans provide a clinically reasonable comparison for PUO plans. 
Analysis of individual components of the utility function showed that when compared to DOO, 
PUO improved absolute predicted LRPFS2y by, on average, 16.6% (range: 2.7–32.6%). 
Improvements in predicted efficacy were met with smaller changes in predicted grade 3–5 
toxicities, with average changes of 0.1% (−0.5–0.5%), −0.9% (−4.0–1.7%), and 1.0% (−0.3–3.5%) 
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for predicted CE3+,2y, RE3+, RILT3+, respectively. PUO resulted in increased target dose, based on 
analysis of PTV D95%, for three of the five patients, with one patient’s PUO plan retaining a 60 Gy 
D95% and another’s deceasing target dose slightly. Comparison of the PUOS1,mod utility metrics to 
the final PUO plan metrics showed that the incorporation of clinically relevant hard constraints 
reduced the potential maximum plan utility by, on average, 0.03 (0.00–0.14). Patient 3 had the 
largest decrease, resulting mainly from the constraints on maximum esophagus and cord doses. 
 
Figure 4.5. Utility results for the original clinically delivered 3DCRT plans and retrospective VMAT, DOO, 
and PUO replans for the five patients used for plan comparison. Results include overall plan utility (left), 
LRPFS2y (middle-top), CE3+ (right-top), RE3+ (middle-bottom), RILT3+ (right-bottom). As an example, 
Patient 1 estimated probabilities for LRPFS2y, CE3+,2y, RE3+, and RILT3+ were 53.6%, 4.3%, 0.4%, and 
3.9%, respectively for Dose-Only Optimization (DOO) and 86.2%, 4.8%, 2.1%, 7.4%, respectively for 
Prioritized Utility Optimization (PUO). Therefore, the overall plan utility improvement using PUO is 
calculated as [0.862 − (0.048 + 0.021 + 0.074)] − [0.536 − (0.043 + 0.004 + 0.039)] = 0.719 − 0.450 = 0.269. 
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For patients 1 and 2, PUO led to large utility improvements over DOO. These 
improvements were mainly driven by increases in predicted LRPFS2y, as visualized in Fig. 4.5, 
with the predicted probability of RILT3+ moderately increasing and probabilities of RE3+ and RP3+ 
remaining similar. The PUO plan for patient 3 had a moderate increase in utility compared to the 
DOO plan caused by increasing predicted LRPFS2y with similar overall predicted toxicity risk. For 
patients 4 and 5, slight utility improvements in PUO plans were driven by improved predicted 
LRPFS2y and decreased probabilities of RE3+ and RILT3+. For Patient 5, PUO planning also 
slightly decreased the predicted probably of CE3+,2y. 
 Absolute and relative DVHs in Figs. 4.6 and 4.7 show comparisons of the DOO and PUO 
plans for patients 2 and 4, respectively. For patient 2, a large increase in target dose was noted with 
non-proportional increases in esophagus and cord doses. For patient 4, the PUO method slightly 
improved target coverage and decreased mean lung dose and maximum esophagus dose. Mean 
cardiac dose remained similar between the two methods, but the PUO plan increased maximum 
cord dose by 24.8 Gy. Variable increases in maximum cord dose were present in all PUO plans, 
since a cord toxicity risk model was not included in the Stage-1optimization model. However, all 
maximum cord doses remained below 45 Gy as enforced by the hard constraint.  
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Figure 4.6. Absolute (top) and relative (bottom) DVH comparisons between the DOO plan (dashed) and the 
PUO plan (solid) for Patient 2. 
 
 
Figure 4.7. Absolute (top) and relative (bottom) DVH comparisons between the DOO plan (dashed) and the 
PUO plan (solid) for Patient 4. 
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4.5 Discussion 
The current clinical standard for RT planning, employing objective functions based upon 
standardized dose metrics, does not adequately account for patient variability within the 
optimization process. In many cases, these objectives are based on historical rates of control or 
toxicity in a patient population without incorporating personalized factors related to the 
radiosensitivity of tumors and OARs. Additionally, most cost functions require user-assigned 
weights for the dose penalties, relying on the expertise of planners and physicians to subjectively 
determine the appropriate weights for a patient. Through this method, allowable planning trade-
offs, based on treatment outcomes rather than dose metrics, could be inconsistently decided upon 
since they are not directly prioritized or optimized. The proposed method presented in this study 
aims to augment this standard approach by facilitating a direct exploration of planning trade-offs 
based on patient-specific predictive models of efficacy and toxicity. Through the implementation 
of a utility-based objective, we believe our strategy offers a more intuitive, tunable approach to 
balance a patient’s potential therapeutic benefit and risk. The proposed method integrates the 
ability for non-uniform weighting of predicted toxicities in an interpretable manner with direct 
relation to the predicted probabilities of treatment outcomes. Therefore, toxicity weights (θ’s) can 
be elicited directly by determining the relative harm associated with a given toxicity compared to 
a given efficacy metric. These values could be assigned independently by a clinician prior to plan 
creation, potentially incorporating patient input, or based on expert consensus opinion determined 
through a method similar to Hobbs et al.140 
We demonstrated the feasibility of this method in a small cohort of NSCLC patients, which 
is a population of interest given the evident trade-offs between local control and lung, heart, and 
esophageal toxicities in RT planning. Additionally, failure of the RTOG 0617 randomized trial to 
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demonstrate improved outcomes at higher doses suggests that utilization of dose escalation in the 
treatment of NSCLC may only be beneficial for a subset of patients.136,141,142 Our method provides 
a quantitative approach for determining which patients may benefit from dose escalation or 
redistribution based on patient-specific clinical factors and biomarkers while also accounting for 
patient geometry and OAR dose limits. 
While this study illustrates the potential for the proposed planning strategy, it does have 
several limitations. Although we compared plan utility metrics between multiple planning 
methods, DVH comparison was limited to the DOO and PUO plans prior to leaf sequencing and 
final volumetric dose calculation due to dose discrepancies between optimal plans from the 
optimizer and plans imported, sequenced, and calculated inside of our TPS. This discrepancy has 
been previously noted in other optimization methods and is normally addressed through updating 
the optimization process with intermediate full dose calculations.143 However, in our hierarchical 
approach, this update process could invalidate hard constraints. Future work will look at addressing 
this discrepancy through the implementation of a fluence smoothing optimization stage, 
heterogeneity constraints, or a correction step similar to that presented in Zarepisheh et al.144 
Our study did not evaluate the effect of beam angle selection on the optimization process 
or achievable plan utility. Further investigation will be required to determine this impact of this 
and if utility could be improved through beam angle optimization. Alternatively, arc-based IMRT 
delivery methods, such as VMAT, could be used to alleviate the need for beam angle selection. 
However, constrained hierarchical optimization techniques for VMAT are currently limited and 
will require additional development.  
 The PUO approach facilitates the use of personalized dose-response models in the 
optimization process but aggregated response models could also be utilized. In testing this method 
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for NSCLC patients, we used previously developed models of response based upon patients treated 
with 3DCRT. Ideally, modeling would be based on a cohort that was treated with the same delivery 
technique as that being optimized since dose response could be, in part, correlated to the underlying 
dose distribution. This distribution, particularly within OARs, could systematically differ between 
varying treatment delivery techniques. While our approach optimizes a patient’s tumor dose, rather 
than assigning a fixed dose goal prior to optimization, modeling for this aspect is challenging 
because it requires previously treated patients to receive a range of prescription doses to determine 
the relationship between treatment efficacy and dose. In the era of increasingly uniform 
prescription doses, such as the 60 Gy standard-of-care for NSCLC patients, modeling dose-based 
efficacy may not be fully possible. In the absence of an efficacy model, the PUO strategy could 
still be utilized to reduce total toxicity burden at a fixed prescription dose. 
 Our initial results from this method demonstrate that plan utility for NSCLC patients has 
the potential to be improved, although drawing additional conclusions from the results is limited 
by the small sample size. Additionally, we did not investigate the effects of potential error and 
uncertainty in the dose-response models or the selection of θ values on the optimization process 
and resulting plans. Future studies will aim to address this through application of the PUO strategy 
in additional disease sites and on larger cohorts of patients. 
4.6 Conclusions 
 We developed and studied an inverse IMRT planning strategy where patient-specific 
radiosensitivities of tumors and normal tissues are directly factored into the optimization objective. 
Through this approach, we aim to improve a patient’s overall RT outcome by balancing potential 
therapeutic benefit with the associated risk in an interpretable and tunable manner. First, a patient’s 
overall plan utility, based upon personalized models of biological response, is maximized subject 
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to relevant clinical constraints. Then, through a hierarchical optimization technique, a typical dose-
based objective function is minimized while attempting to retain the maximal plan utility.  
 We demonstrated the feasibility of the approach using a cohort of NSCLC patients with 
previously developed predictive models of treatment efficacy and toxicity based on demographics, 
clinical factors, and biomarkers. The proposed planning method generated plans conforming to 
clinical constraints with improved overall utility when compared to plans generated using typical 
dose-based objectives. 
4.7 Extensions and Future Work 
4.7.1 Visualization of planning trade-offs 
 Development of the previously-described, customized RT optimization framework has 
allowed for additional testing of optimization concepts and ideas to inform future RT planning 
strategies. One important consideration for future treatment planning strategies, including 
functional avoidance planning, is that the ability to redistribute dose between normal tissues, while 
still achieving acceptable disease control, may be inherently limited by current treatment planning 
guidelines. Depending on patient geometry and treatment goals, a treatment planner may only be 
able to reduce the dose to a given OAR by a limited amount before another OAR dose exceeds a 
guideline. Additionally, trade-offs between reducing dose to multiple OARs may not be uniform, 
with the reduction of dose to one OAR potentially causing a disproportional increase in dose to 
another OAR. In many clinical RT optimization systems, it may be challenging to understand and 
visualize these trade-offs within the range of acceptable clinical dose limits because systems do 
not allow for the inclusion of hard constraints that cannot be violated during plan optimization. 
Since our optimization facilitates the inclusion of hard constraints, we tested a method to map the 
clinically acceptable trade-off space between competing OARs. In part, this relates to the concept 
 112 
of multi-criteria optimization (MCO), also known as multi-objective optimization, which has been 
an ongoing area of development in RT optimization for the last decade.145-147 In MCO IMRT 
optimization, competing planning objectives (e.g., dose metrics, tumor coverage metrics) are 
assigned varying weights during plan optimization to determine the Pareto optimal front for 
treatment planning.145 A given RT plan is considered to be on the Pareto optimal, or non-
dominated, front if none of the planning objectives can be improved without degrading a 
competing planning objective. We are working to extend this concept to lung RT planning in the 
context of our optimization system. 
 To explore the clinically available trade-off space in lung RT planning, we optimized four 
IMRT plans for each patient with clinical dose guidelines used as hard constraints. For three of the 
plans, we generated non-dominated RT plans by focusing the optimization on only one relevant 
OAR dose metric as a planning objective, either lung-GTV mean dose, esophagus max dose, or 
heart mean dose. Hard constraints were used to maintain a minimum PTV dose of 60 Gy with less 
than 115% hot spots. We also generated a representative plan in which all three planning objectives 
were included in an equally-weighted objective function. Figure 4.8 shows a visual comparison 
between the dose metrics for the four plans in the form of triangular radar plots for two of the 
patients. Each vertex on the solid colored lines within the plots represent dose metrics for one of 
the three non-dominated plans and the dashed-line vertices represent the equally weighted plan. 
Although linear trade-offs are not necessarily clinically feasible, plotted linear connections 
between dose metrics for a given plan are used to help visualize the tradeoff space. Within each 
triangle, the remaining white area represents a range of doses that are feasible and clinically 
acceptable. The interior gray-shaded region represents plans that are clinically infeasible, the 
exterior gray-shaded region represents plans that are suboptimal. It is important to note that the 
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linear relationship between the competing dose metrics is shown for visualization purposes and 
may not be directly representative of solutions balancing multiple objectives.  
 
Figure 4.8. Example visualization of dose trades-off for lung IMRT plans for two patients, Patient A (left) and 
Patient B (right). 
 
For both example patients, it is evident that reductions in mean dose to the lung 
disproportionally increase the mean dose to the heart. For Patient B, a 2 Gy decrease in mean lung 
dose could result in a 14 Gy increase in mean heart dose. Additionally, reducing lung dose may 
disproportionally increase esophagus max dose, with a 1.5 Gy decrease in mean lung dose for 
Patient A increasing the esophagus max dose by nearly 10 Gy. In both cases, focusing the 
optimization only on reducing mean lung dose provides only up to a 2 Gy decrease in dose, 
possibly demonstrating that reductions in mean lung dose are inhibited by the included hard 
constraints. While this initial work demonstrates that certain trade-offs between OAR doses may 
be inherently limited and that decreasing dose to certain OARs may disproportionally increase 
dose to other OARs, determining the underlying trends between trade-offs for lung RT will require 
application of this method over a larger cohort of patients. 
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4.7.2 Physician Survey of utility weights 
 One potential benefit of the utility optimization approach is that it directly incorporates the 
ability for physicians, and potentially patients in the future, to prioritize meaningful components 
of the objective function for RT plan optimization. Historically and in many current clinical 
applications, the priorities for treatment planning objectives are defined by setting weights for 
various dose metrics grouped into a weighted-sum objective function. Although these dose metrics 
are typically related to a treatment endpoint or toxicity, their relationship to an outcome is generally 
an implicit translation of a toxicity model.  Given the typical sigmoid-shaped outcome models 
(e.g., TCP, NTCP) used in radiation therapy, the combined weight and dose metric is unlikely to 
accurately represent the changing probability of a treatment outcome across a range of doses. 
Therefore, it is difficult to derive the clinical meaning from changes in dose while comparing plans 
or optimizing a plan. Although previous studies have attempted to address this through the 
incorporation of biological models in the optimization process, current clinical biological 
optimization tools either do not allow weighting of the biological objective function or the clinical 
meaning of assigned weights are obscured due to the use of convex transforms of the models for 
optimization.133-135 Unlike previously developed biological optimization tools, our implementation 
of utility-based planning retains the clinical meaning behind assigned weights because the models 
are not transformed but rather converted into highly representative PWL approximations. Since 
this weighting approach deviates from the current standard-of-practice in RT planning, we have 
started to gather physician input on how to weight the probability of toxicity outcomes for lung 
RT.  
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 An online survey, shown in Appendix B, was designed and distributed using Qualtrics 
(Provo, UT) to gather preliminary feedback from physicians for weighting grades 2–5 radiation-
induced lung toxicity, radiation esophagitis, and cardiac events within 2 years of treatment. In the 
survey, physicians are asked to assign relative weights to toxicity grades independently based on 
local-regional progression having a fixed weight of 100. In this context, an assigned relative weight 
of 0 means that the toxicity is not harmful, a weight of 100 means that the toxicity is equally as 
harmful as local-regional progression, and a weight of 200 means that the toxicity is twice as 
harmful as local-regional progression. These assigned weights can then be directly included in the 
utility function by dividing by 100 to normalize the relative weights to the efficacy metric having 
an implicit weight of 1. Table 4.5 shows the preliminary results from the survey completed by 7 
physicians with varying experience practicing in radiation oncology and varying knowledge of the 
utility-based optimization project. This early feedback suggests that radiation esophagitis is 
considered less harmful than other toxicities across grade 2–4 toxicities. However, all grade 5 
toxicities, toxicities resulting in patient death, averaged similar weighting in the range of 220. This 
suggests that grade 5 toxicities are consistently considered at least twice as harmful as local-
regional progression. Physician variability in the assigned weights also appears to be large, with 
grade 3 assigned toxicity weights ranging from 5 to 80, and grade 4 assigned toxicity weights 
ranging from 20 to 154. It is yet to be determined whether this large range is a result of variable 
understanding of the relative weight concept, or if it represents true variability in how physicians 
currently consider treatment toxicities. Additional survey responses and feedback will be required 
to help make these determinations. Furthermore, additional consideration is required to convert 
the individually weighted toxicity grades into a single weight for toxicities grouped across a range 
of grades. For example, in our lung utility planning study, toxicity outcomes include grades 3–5 
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in a single model due to overall low incidence of the individual toxicity events within each grade. 
Although we could ask physicians to assign weights based on grouped grades of toxicity, initial 
feedback showed that it is challenging to assign a weight without a clear understanding of the 
underlying distribution of individual toxicity grades within a group. 




4.7.3 Head and neck total toxicity burden optimization 
Head and neck cancer (HNC) RT typically results in high doses of radiation to OARs, 
contributing to decreased quality-of-life (QOL) resulting from of xerostomia and dysphagia.148-150 
Current RT planning methods attempt to control for these types of toxicities by minimizing dose-
volume parameters during optimization. However, dosimetric trade-offs made during treatment 
planning may be inconsistent with improving or balancing a patient’s overall predicted total 
toxicity burden (TTB) because the relationship between physical dose and the response of OARs 
is typically considered non-linear. Prior studies have incorporated toxicity models in the treatment 
planning process but are limited by the use of a combined, singular dose and biological objective 
function, or by the implementation of convexified toxicity models that obscure the relative 
importance of each toxicity metric in the objective function.135  By modifying our utility 
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optimization approach, we can directly optimize and potentially reduce the predicted TTB of a 
patient’s RT plan while remaining within current clinical dosimetric guidelines. 
We implemented a prioritized approach to TTB optimization using the in-house 
optimization plugin developed for prioritized utility-based planning. In this case, Stage 1 of the 
optimization process was reconfigured to minimize TTB, defined as the weighted-sum of 
toxicities. This change is effectively equivalent to using a fixed efficacy metric in the utility 
equation.  Prioritized TTB (P-TTB) plans were optimized using a similar two stage hierarchal 
method for inverse IMRT planning. In the first stage, TTB is minimized subject to high-priority 
OAR dose limits, target prescription, and target coverage requirements. Weights for the toxicities 
directly represent the relative undesirability of toxicities. In the second stage, a weighted-sum 
dose-metric objective is minimized, similar to current clinical practice. This stage is subject to the 
same constraints as the first stage, but an additional constraint for TTB is incorporated based on 
the optimal solution of the first stage. 
Due to the complexity of HNC plans, with multiple small OARs typically in close 
proximity to the target volumes, an improved point sampling method was implemented. Instead of 
generating sets of pseudorandom points for the influence matrix calculation, we implemented point 
sampling based on a low discrepancy (quasirandom) sequence with the ability to sample a portion 
of points directly on the surface of the structure. The additive recurrence sequence, when combined 
with pseudorandom localized jittering, improved mean distance between points and minimum 
distance between sampling points by approximately 20%.  With the addition of surface point 
sampling, this allowed for decreased point sampling density, reducing optimization model 
complexity, while still maintaining an accurate representation of the structure dose. Additionally, 
to reduce optimization solver time, the usage of crossover to produce a basic solution from the 
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barrier solver solution was eliminated. While this means that small infeasibilities may still exists 
in the final solution, these infeasibilities were found to have negligible impact on the final dose 
distribution. Initial tests suggest that these modifications reduce model complexity and solver time 
without degrading plan quality, and may also improve agreement between the optimized plan and 
deliverable plan (generated after leaf sequencing and final dose calculation). In the future, these 
modifications will be applied to lung prioritized utility-based planning to determine if these 
changes improve the optimization process and impact optimization results. 
Using this approach, we retrospectively generated IMRT plans for 5 HNC patients and 
compared the resulting plans to IMRT plans generated without the added TTB constraint. Both 
plans consisted of 9 equally-spaced, non-opposing beams with the same OAR dose limits and 
dose-metric objective. Target dose requirements were based on simultaneous integrated boost 
prescriptions of 70 and 56 Gy delivered in 35 fractions. TTB was calculated using previously 
published NTCP models for dysphagia and xerostomia.151,152 Dysphagia was based on increase in 
aspiration or HNQOL score > 81 as a function of pharyngeal constrictor (PC) mean dose.152 
Xerostomia was based on parotid flow ratio <25% of pretreatment (grade 4) or xerostomia 
questionnaire > 73 as a function of parotid gland (PG) mean dose.151 
Our optimization engine successfully generated P-TTB plans for all five patients while 
maintaining similar target coverage to the standard dosimetrically optimized plans. P-TTB plans 
resulted in average absolute NTCP reductions of 15.5% (range: 0.2–53.4%) for dysphagia and 
20.5% (1.9–68.5%) for xerostomia. These changes correlate to average mean dose decreases of 
6.9 Gy (0.2–22.7 Gy) for PC and 10.2 Gy (1.2–33.5 Gy) for PGs. P-TTB planning resulted in 
greater fluence modulation and higher doses to OARs, such as the larynx, not included in the 
calculation of TTB. 
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The P-TTB planning, similar to the utility method, offers an intuitive optimization 
approach to balancing trade-offs between various treatment outcomes and has the ability to directly 
reduce and redistribute predicted toxicity which may aid in improving QOL for HNC patients 
receiving RT. Future studies will focus on the incorporation of personalized toxicity models for 
HNC patients in addition to addressing concerns of increased plan modulation and dose to non-
modeled structures. 
4.7.4 Virtual Radiotherapy Trial Suite 
 Retrospective testing of new treatment planning strategies is critical to inform design and 
determine the potential clinical benefit from new interventions. With increasing complexity and 
personalization in modern treatment planning, the evaluation of new treatment planning techniques 
prior to clinical implementation would benefit from more robust testing across larger cohorts of 
patients. However, testing and evaluation has historically required a large amount of manual effort 
dedicated to generating treatment plans, manipulating parameters, and extracting data for analysis. 
To address this, we are currently developing a software framework, called the virtual radiotherapy 
trial suite, that will allow larger scale testing and analysis of new treatment planning techniques, 
algorithms, and optimization strategies. 
 This software suite interacts with our TPS through ESAPI to access clinical images and 
commercially available planning algorithms (e.g., dose calculation, knowledge-based planning). 
Data from the TPS, along with data from external sources, can then be used to test various 
treatment strategies under consideration for clinical implementation, such as utility or TTB 
optimization. In addition to testing treatment planning techniques, the framework can also be used 
as a data mining and extraction tool for rapidly gathering and exporting data from the Eclipse/Aria 
environment with limited user-interface interaction. As shown in Figure 4.9, the system is set up 
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as a flexible framework that manages batch tasks that compose a ‘trial’ for a set of patients. The 
tasks are developed independently of the system and compiled into function code blocks that 
interact with the suite through a common pathway for data transfer and progress reporting. While 
this system is currently still under development, we have recently demonstrated the ability to 
rapidly test different dose calculation algorithms on a cohort of lung patients (example user 
workflow shown in Appendix C). In the future, we will utilize this system to test prioritized utility 
and TTB optimization across larger cohorts of patients to determine the potential clinical impact 
of the methods. Additionally, this will allow us to more rapidly test the effects of differing 
biological models, component weights, patient factors, and optimization parameters on the 
treatment planning process with the goal of developing clinically relevant implementations of the 
proposed treatment planning strategies.  
 
 
Figure 4.9. Conceptual diagram for the virtual radiotherapy trial suite (gray shaded background) connected to 
the TPS, Eclipse, through ESAPI. 
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Chapter 5  
Conclusion, Summary, and Future Directions  
 
This dissertation focuses on multiple aspects related to increasing personalization in RT 
with the goal of improving disease control and lowering toxicity rates. Broadly across RT, 
additional improvements and technological innovations are needed to move the field into an era of 
precision medicine, in which a patient’s RT treatment is guided by the patient’s individual 
characteristics rather than historical population level models and simple patient stratifications.  
This will require advancements in imaging, spatial correlation, treatment modalities, delivery 
methods, outcomes collection, predictive modeling, and treatment optimization in addition to 
advancements in many other sub-fields of RT.  
Advancements in imaging and deformable registration will allow better monitoring of 
patients for anatomical and physiological changes throughout the RT treatment course and provide 
clinicians with the ability to determine when a patient may benefit from modification of the 
treatment plan in a timely manner. Additionally, advancements in optimization and outcome 
modeling will drive our ability to tailor the treatment specifically to the patient through 
personalized dosing, normal tissue sparing, and plan adaptation based on patient-specific predicted 
response, accounting for the individualized potential for disease control and risk of treatment 
associated toxicity.  Overall these advancements can not only aid in improving the therapeutic 
ratio for individual patients, but can help capture more accurate treatment data which, when paired 
with robust patient characteristic and outcome reporting, can be used to develop modern, highly-
predictive patient response models that go beyond a ‘one size fits all’ approach currently employed 
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in RT. In this dissertation, specifically, improvements in DIR and plan optimization are explored 
as contributions towards improving personalization in RT. 
In Chapter 2, we characterized the clinical accuracy of an intensity-based DIR algorithm 
and explored tuning of algorithm parameters to improve accuracy and robustness. Although 
intensity-based DIR has the benefit of not requiring contouring or landmark identification prior to 
registration, which makes it an attractive option for widespread clinical use and use in 
unsupervised offline adaptive RT, we found that the accuracy of the B-spline, mutual information 
based algorithm tested only achieved clinically acceptable accuracy in certain clinical imaging 
scenarios. Algorithm parameter tuning, which is not typically analyzed prior to clinical use of these 
types of DIR algorithms, was found to improve registration accuracy, but only for lung imaging 
scenarios where bronchial and vessel bifurcations can drive the registration algorithm to deform 
locally based on clear tissue differentiation. For HN imaging, registration parameters deviating 
from the default values were shown to have little clinical impact on registration accuracy. This 
suggests that different approaches, beyond algorithm tuning, may be required to improve accuracy 
for imaging scenarios without large contrast differences between deforming tissues or organs. 
These approaches could include modifications to the B-spline method, such as irregular spacing 
of B-spline control points to better model deformations at the boundaries between tissues. 
Additionally, intensity-based DIR accuracy is highly dependent on the quality of the images being 
registered. Therefore, improving imaging quality prior to registration through tuning acquisition 
parameters or improving reconstruction techniques should be considered, particularly for CBCTs 
in the use case of daily offline adaptive RT using DIR.155 
In Chapter 3, we demonstrated that incorporating local volumetric response into a 
previously developed biomechanical model-based DIR algorithm could improve longitudinal liver 
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registration accuracy. In this study, we first modeled liver normal-tissue volumetric response based 
on radiation dose and applied modified thermal linear expansion coefficients to drive volume 
change at the element level rather than relying on external modeling forces to model response. We 
then applied the external, surface forces to resolve the spatial differences between the two models 
of the liver resulting from typical anatomical and physiological motion.  This novel addition to the 
biomechanical DIR process has the ability to improve our ability to correlate functional changes 
that occur in the liver during and after RT and spatially relate observed changes to delivered 
dose.75,76 Beyond the liver, this method has the ability to be applied to other anatomical locations 
(e.g., parotid gland, stomach, bladder, rectum, etc.) where local mass loss or gain impacts the 
accuracy of current DIR technologies and can potentially aid in resolving these volumetric changes 
without generating unrealistic deformation patterns. This DIR method, along with other geometric 
DIR methods, has the downside that corresponding contours and landmarks need to be identified 
in the images prior to registration.25 Although historically this has relied on manual contouring, a 
time-consuming process, advancements in machine learning, particularly those in 3D 
convolutional neural networks, have improved the ability to accurately segment structures 
automatically with limited human intervention.156-159 The continued improvement of these auto-
segmentation technologies for the liver and other structures will lead to improved accuracy and 
efficiency in geometric-based DIR, potentially leading to more widespread clinical adoption of 
these methods.  
In Chapter 4, we demonstrated a potential clinical application for modern, personalized 
outcome models in RT. We developed and implemented a novel, but also generalizable, 
optimization strategy, based on the concept of plan utility, that facilitates direct incorporation of 
patient-specific efficacy and toxicity models into the treatment planning process without disrupting 
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current clinical standards of practice. By merging personalized, biological optimization with 
traditional dose-metric based optimization in a prioritized approach, we offer clinicians an 
opportunity to start exploring individualized treatment planning tradeoffs in an intuitive manner 
without requiring a complete overhaul of the current treatment planning process. Using previously 
developed models for efficacy and toxicity that factor in patient-specific clinical factors and 
predictive biomarkers for NSCLC patients, we demonstrated that this approach is feasible and has 
the potential to improve treatment outcomes through non-uniform dose escalation and OAR 
sparing in a limited patient population. The results from this feasibility study are encouraging and 
support the need for further investigation of this method across a larger cohort of patients. 
Additionally, a reformulation of the prioritized utility method, accounting only for toxicity burden, 
was introduced for HN cancer treatment and was demonstrated to be a feasible optimization 
strategy when applying current NTCP models. Future work will include developing new patient-
specific toxicity models for HN cancer patients, similar to those available for NSCLC patients, to 
improve personalization in this method. 
The work encompassed in this dissertation highlights two important aspects to help shift 
RT towards an era of precision medicine. First, improvements in DIR offer the increased ability to 
accurately determine spatial relationships and patient-specific tissue response between imaging 
acquired at different time points throughout a patient’s treatment course. Accurate spatial mapping 
of functional imaging could facilitate the generation of new dose response models that more 
directly correlate localized changes, computed as longitudinal functional changes during 
treatment, with delivered dose. Additionally, through offline adaptive RT including dose 
accumulation, improved DIR accuracy and automation should translate into better estimations of 
a patient’s delivered dose, which in turn could increase the accuracy of efficacy and toxicity 
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prediction models which have historically been based on planned dose.160,161 Once refined, patient-
specific predictive models are generated, the models need to be incorporated back into the 
treatment planning process for future patients to realize benefits of this work. Our proposed 
optimization strategy, which directly incorporates these types of patient-specific models, offers a 
potential solution for real clinical application, wherein newly developed predictive models can be 
progressively integrated into the planning process without explicitly requiring such models for 
every clinically relevant structure. In summary, the ability to generate patient-specific response 
models and intervene based on such models offers exciting opportunities in RT that aim to address 












Figure A.1. Fully functional dose accumulation prototype dashboard showing the customizable treatment 






Figure A.2. Fully functional dose accumulation prototype dashboard showing dose and motion tracking of a 












Figure B.1. Pages 1 and 2 of the online survey to gather utility weights from physicians. 
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Figure B.2. Page 3 of the online survey to gather utility weights from physicians. 
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Figure C.2. Virtual radiotherapy trial suite workflow Step 2: Loading in functional .dll blocks and 




Figure C.3. Virtual radiotherapy trial suite workflow Step 3: Running the trial and checking the progress of 
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